



UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES  
F. EDWARD HÉBERT SCHOOL OF MEDICINE  
4301 JONES BRIDGE ROAD  
BETHESDA, MARYLAND 20814-4799



GRADUATE AND  
CONTINUING EDUCATION

APPROVAL SHEET

TEACHING HOSPITALS  
WALTER REED ARMY MEDICAL CENTER  
NAVAL HOSPITAL, BETHESDA  
MALCOLM GROW AIR FORCE MEDICAL CENTER  
WILFORD HALL AIR FORCE MEDICAL CENTER

Title of Thesis: "Heterogeneity of Opioid Binding  
Sites in Guinea Pig Spinal Cord"

Name of Candidate: Gary Dean Zarr  
Master of Science Degree  
November 30, 1984

Thesis and Abstract Approved:

Lewis Cronow  
Committee Chairperson

30 November 1984  
Date

Sheila M. Muldoon  
Committee Member

30th Nov '84  
Date

Cinda J. Helke  
Committee Member

30 Nov 1984  
Date

Brian M. Cox  
Committee Member

30 Nov 1984  
Date

The author hereby certifies that the use of any copyrighted material in the dissertation manuscript entitled:

"Heterogeneity of Opioid Binding  
Sites in Guinea Pig Spinal Cord"

beyond brief excerpts is with the permission of the copyright owner, and will save and hold harmless the Uniformed Services University of the Health Sciences from any damage which may arise from such copyright violations.



Gary Dean Zarr  
Department of Pharmacology  
Uniformed Services University  
of the Health Sciences

## Abstract

Title of Thesis: Heterogeneity of Opioid Binding Sites In Guinea Pig Spinal Cord

Gary Dean Zarr MAJ/ANC, Master of Science, 1984

Thesis directed by: Brian M. Cox, Ph.D., Professor, Department of Pharmacology

High concentrations of opioid peptides derived from both proenkephalin and prodynorphin are present in spinal cord, and studies of their localization within spinal cord suggest the opioids may be involved in the regulation of both sensory and motor functions. Sensory deficits and disturbed motor functions following the local administration of opiates or opioid peptides to spinal cord also suggest a multiplicity of endogenous opioid regulatory functions in this tissue.

Studies of radiolabelled opioid ligand binding to both regional sections or whole spinal cord membrane preparations confirm that saturable high affinity binding sites in this tissue show heterogeneity of binding properties. However, many of these studies have been conducted at non-physiological temperatures and in buffers lacking major physiological cations. Past studies have shown that opioid receptor binding is significantly affected by the presence of major physiologic cations as well as by variations in temperature. In this study of radiolabelled saturable high affinity stereoselective specific binding sites in whole spinal cord as well as lumbo-sacral spinal cord, conditions which parallel the *in vivo* situation were adhered to as closely as possible. The saturable binding of [ $^3\text{H}$ ] Tyr-D-Ala-Gly-MePhe-NH(CH $_2$ ) $_2$  OH ([ $^3\text{H}$ ]DAGO), [ $^3\text{H}$ ]D-Ala $^2$ -D-Leu $^5$  enkephalin ([ $^3\text{H}$ ]DADLE), and [ $^3\text{H}$ ]ethylketocyclazocine ([ $^3\text{H}$ ]EKC) in spinal cord membrane preparations with Na $^+$  and other major physiological cations at pH of 7.4 and temperature of 37 $^{\circ}\text{C}$  were studied in the presence and the absence of selective blocking ligands. In addition, displacement studies of the above radiolabelled compounds with a variety of unlabelled compounds in the presence and

absence of site selective opioid blocking drugs were performed to establish receptor subtype selectivities for a variety of ligands and to verify the  $B_{MAX}$  values that were derived from Scatchard analyses. Hill slope analysis was carried out before and after appropriate selective opioid blocking drugs were added to the displacement assay tubes and an increase of the Hill slope value toward unity was taken as evidence that the opioid blocking drug had produced a more homogeneous receptor population. Experiments indicate that both the radiolabelled and unlabelled drugs used in the binding assay were stable under the assay conditions for up to 60 min without necessitating the addition of peptidase inhibitors. Isolated binding sites with mu ( $\mu$ ), delta ( $\delta$ ), and kappa ( $\kappa$ ) receptor type characteristics were readily identifiable.

Ligand affinities measured in the presence of major physiologic cations and temperature may give more useful indices of opiate drug binding site selectivity. Additionally, ligand receptor selectivity measured under conditions of physiological cation concentration and temperature should be more useful for comparison with pharmacologic selectivity and drug concentrations mediating pharmacological effects *in vivo*.



**HETEROGENEITY OF OPIOID**

**BINDING SITES IN**

**GUINEA PIG SPINAL CORD**

**by**

**Gary Dean Zarr**

**Thesis submitted to the faculty of the Department of Pharmacology  
Graduate Program of the Uniformed Services University of  
the Health Sciences in partial fulfillment of the  
requirements for the degree of  
Master of Science 1984**

To my family and friends who have always given me support and encouragement during good times as well as times of adversity.

## ACKNOWLEDGEMENTS

I wish to express my appreciation to the members of my committee, Dr. Lewis Aronow, Dr. Cinda Helke, Dr. Sheila Muldoon, and Dr. Brian Cox for their interest in my research and their helpful suggestions and comments. I am especially indebted to Dr. Linda Werling, who as a teacher and friend, not only taught me how to set up an experiment, but also gave many hours of assistance in computer modeling of the results.

I have been very fortunate to have had Dr. Brian Cox as my primary advisor while I have been at USUHS. Without his knowledge and support this work would not have been possible.

I am grateful to Steve Brown for his many hours of technical assistance during this research project.

## TABLE OF CONTENTS

	Page
APPROVAL SHEET	i
COPYRIGHT STATEMENT	ii
ABSTRACT	iii
TITLE PAGE	v
DEDICATION	vi
ACKNOWLEDGEMENT	vii
TABLE OF CONTENTS	viii
LIST OF FIGURES	xi
LIST OF TABLES	xiv
CHAPTER ONE: INTRODUCTION	1
<i>In Vitro</i> Evidence For Opioid Receptors	1
Isolation of Endogenous Opioid Peptides	2
Heterogeneity of Opioid Receptors	3
Location of Opioid Receptors	6
Regional Distribution of Opioid Receptors	6
Ionic Effects On Opioid Receptor Binding	9
GTP Effects On Opioid Receptor Binding	10
Transduction of Opioid Receptor Binding	11
Intrathecal Opioid Analgesia	13
CHAPTER TWO: MATERIALS AND METHODS	19
Materials	19
Methods	19
Preparation of Spinal Cord Membranes	19
Protein Assay	20
Radioligand Binding	21

Stability Check of Radioligands	22
Stability Determination of Unlabelled Ligands	23
CHAPTER THREE: RESULTS	24
TLC Radiolabelled Ligands	24
Stability of Unlabelled Ligands	24
Characterization of Specific Binding of Labelled Ligands	24
Characterization of Specific Binding of [ $^3\text{H}$ ] DAGO	28
Saturation Curves of [ $^3\text{H}$ ] DAGO In Whole Spinal Cord	33
Displacement Curves of [ $^3\text{H}$ ] DAGO In Whole Spinal Cord	34
Saturation Curves [ $^3\text{H}$ ] DAGO Lumbo-sacral Cord	38
Displacement Curves of [ $^3\text{H}$ ] DAGO in Lumbo-sacral Cord	38
Characterization of Specific Binding of [ $^3\text{H}$ ] EKC	42
Saturation Curves [ $^3\text{H}$ ] EKC	44
Displacement Curves of [ $^3\text{H}$ ] EKC	45
Saturation Curves of [ $^3\text{H}$ ]EKC With DAGO And U50488H Block	47
Characterization of Specific Binding Of [ $^3\text{H}$ ] DADLE	54
Saturation Curves [ $^3\text{H}$ ] DADLE	58
Displacement Curves of [ $^3\text{H}$ ] DADLE	59
Saturation Curves [ $^3\text{H}$ ] DADLE At Isolated $\alpha$ Site	58
CHAPTER FOUR: DISCUSSION	62
Heterogeneity of Spinal Opioid Receptors	62
Lumbo-sacral Spinal Cord Opioid Receptors	64
Mu Receptor Subtypes	66
Delta Opioid Receptors	67
Nalbuphine HCl Affinities at Isolated $\kappa$ and $\mu$ Opioid Receptor Sites	67
Comparison of <i>In Vitro</i> $K_D$ and $K_I$ Values With <i>In Vivo</i> $\text{EC}_{50}$ Estimates	68
CHAPTER FIVE: CONCLUSIONS	70



## REFERENCES

72

## List of Figures

<u>Figure</u>	<u>Page</u>
1. Plot of TLC results for [ $^3$ H]DADLE and [ $^3$ H]DAGO	26.
2. Plot of TLC results for [ $^3$ H]EKC	27.
3a. Specific binding of [ $^3$ H]DAGO, [ $^3$ H]DADLE and [ $^3$ H]EKC to whole guinea pig spinal cord membranes as a function of time	30.
3b. Dissociation time curve of specific binding for [ $^3$ H]EKC in guinea pig cortex membranes	30.
4. Specific binding of [ $^3$ H]DAGO, [ $^3$ H]DADLE and [ $^3$ H]EKC to whole guinea pig spinal cord membranes as a function of protein concentration	31.
5a. Specific binding of [ $^3$ H]DAGO to whole guinea pig spinal cord membranes at increasing radioligand concentration	33.
5b. Scatchard transformation of specific binding of [ $^3$ H]DAGO to whole guinea pig spinal cord membranes at increasing radioligand concentration	33.
6. Specific binding of [ $^3$ H]DAGO at 5nM in the presence of increasing concentrations of unlabelled DAGO	35.
7. Specific binding of [ $^3$ H]DAGO at 5nM in the presence of increasing concentrations of unlabelled DAGO, nalbuphine HCl and morphine sulfate (A) or DSTLE and U50,488H (B)	37.
8a. Scatchard transformation of specific binding of [ $^3$ H]DAGO to lumbo-sacral or cervical-thoracic spinal cord membranes at increasing radioligand concentrations.	41.
8b. Specific binding of [ $^3$ H]DAGO at 5nM to lumbo-sacral spinal cord membranes in the presence of increasing concentrations of unlabelled morphine sulfate or U50,488H	41.

9a.	Specific binding of [ $^3\text{H}$ ]EKC to whole guinea pig spinal cord membranes at increasing radioligand concentrations	44.
9b.	Scatchard transformation of specific binding of [ $^3\text{H}$ ]EKC to guinea pig spinal cord membranes at increasing radioligand concentrations	44.
10.	Specific binding of [ $^3\text{H}$ ]EKC at 2nM to whole guinea pig spinal cord membranes in the presence of increasing concentrations of unlabelled DAGO (A) or U50,488H (B)	46.
11.	Specific binding of [ $^3\text{H}$ ]EKC at 2nM to whole guinea pig spinal cord membranes in the presence of increasing concentrations of unlabelled DSTLE without 1 $\mu\text{M}$ DAGO block and with 1 $\mu\text{M}$ DAGO block	48.
12.	Specific binding of [ $^3\text{H}$ ]EKC at 2nM to whole guinea pig spinal cord membranes in the presence of increasing concentrations of unlabelled EKC with and without 1 $\mu\text{M}$ DAGO block (a) or U50,488H with and without 1 $\mu\text{M}$ DAGO block (B)	50.
13.	Scatchard transformation of specific binding of [ $^3\text{H}$ ]EKC to whole guinea pig spinal cord membranes at increasing radioligand concentrations without blocking ligands (A), with 1 $\mu\text{M}$ DAGO block (B) and with 1 $\mu\text{M}$ U50,488H block (C)	53.
14.	Specific binding of [ $^3\text{H}$ ]EKC at 2nM to whole guinea pig spinal cord membranes in the presence of increasing concentrations of unlabelled nalbuphine HCl with and without 1 $\mu\text{M}$ DAGO block	55.
15a.	Specific binding of [ $^3\text{H}$ ]DADLE to whole guinea pig spinal cord membranes at increasing radioligand concentrations	58.
15b.	Scatchard transformation of specific binding of [ $^3\text{H}$ ]DADLE to whole guinea pig spinal cord membranes in the presence and absence of 10nM DAGO block	58.

- |     |  |     |
|-----|--|-----|
| 16. | Specific binding of [ $^3$ H]DADLE at 5nM to whole guinea pig spinal cord membranes in the presence of increasing concentrations of unlabelled DSTLE | 59. |
| 17. | Specific binding of [ $^3$ H]DADLE at 5nM to whole guinea pig spinal cord membranes in the presence of increasing concentrations of unlabelled DAGO  | 61. |

## List of Tables

<u>Table</u>		<u>Page</u>
1.	Computer-derived binding parameters for binding of [ <sup>3</sup> H]DAGO in whole guinea pig spinal cord membranes	39.
2.	Computer-derived binding parameters for binding of [ <sup>3</sup> H]EKC to unisolated and isolated k sites in whole guinea pig spinal cord	56.
3.	Comparison of binding of [ <sup>3</sup> H]DAGO at $\mu$ sites, [ <sup>3</sup> H]DADLE at isolated $\delta$ sites and [ <sup>3</sup> H]EKC at isolated k sites in various neural tissues	63.



## Introduction

### *In Vitro* Evidence For Opioid Receptors

The presence of stereospecific saturable opioid receptor binding sites in neural tissue was initially reported by three independent laboratories (Pert and Snyder, 1973a; Simon et al., 1973; Terenius, 1973). Pert and Snyder (1973a) used [ $^3\text{H}$ ]naloxone as a radioligand to study binding to guinea pig ileum and brain as well as mouse and rat brain. Simon and co-workers (1973) used [ $^3\text{H}$ ]etorphine, an opioid agonist, to study receptor binding in rat brain homogenates. Terenius (1973) used the opioid agonist [ $^3\text{H}$ ]dihydromorphine as a radioligand to study receptor binding in cerebral cortex synaptic membrane fractions. Quantitative analysis of specifically bound drug was determined by separation from free drug in solution by centrifugation (Terenius, 1973), or filtration through glass fiber filters (Pert and Snyder, 1973a; Simon et al., 1973). The advantage of the rapid filtration technique is that a greater portion of the more rapidly dissociating non-specific binding component is washed out during filtration, resulting in improvement in the ratio of specific to non-specific binding. These three laboratories utilized radioligand binding techniques that were first described in principle by Goldstein and co-workers (1971). These investigators used [ $^3\text{H}$ ]levorphanol to describe both saturable and non-saturable non-specific, as well as specific binding. In addition, they showed that specific binding to opioid receptors could be computed by subtracting the amount of labelled opiate bound in the presence of a large molar excess of the unlabelled form of the drug from the amount of binding in the presence of the same concentration of the inactive positive isomer of opiates. Additional opioid receptor binding studies (Pert and Snyder, 1974) showed a maximum of binding at pH 7.4. Pert and Snyder (1974) also showed that temperature and ionic composition affected specific opioid binding. The opioid antagonist [ $^3\text{H}$ ]naloxone in the presence of  $\text{Na}^+$  showed a 1.7 fold increase in specific binding when the temperature was increased from 5°C to 35°C. The opioid agonist [ $^3\text{H}$ ]dihydromorphine in the presence of  $\text{Na}^+$  showed a 7 fold increase in specific binding when

temperature was increased from 5°C to 25°C. Temperatures above 40°C resulted in a reduction of specific binding. Pharmacological relevance of *in vitro* opioid receptor binding studies was established (Pert and Snyder, 1973a,b; Simon et al., 1973) by the fact that the ability of unlabelled opiate drugs to inhibit the specific binding of [<sup>3</sup>H]naloxone or [<sup>3</sup>H]etorphine correlated well with their relative *in vivo* potencies as analgesic antagonists or agonists.

### Isolation of Endogenous Opioid Peptides

The discovery of opioid receptors prompted the search for endogenous opioid like substances. The existence of endogenous receptors that only had high binding affinity for opiate alkaloid substances injected into the body was felt to be unlikely. The existence of endogenous opioid polypeptide substances in whole brain or from pituitary extracts was discovered by several groups (Terenius and Walstrom, 1974; Hughes, 1975a; Teshemacher et al., 1975; Cox et al., 1975). These opioid polypeptides interacted with opioid receptors in the guinea pig ileum (GPI) and mouse vas deferens (MVD) bioassay preparations in a naloxone reversible fashion. The polypeptide identified by Hughes (1975a) was later established by Hughes and his co-workers (1975b) to be two closely related pentapeptides, with the sequences Tyr-Gly-Gly-Phe-Met (methionine enkephalin or [Met<sup>5</sup>]enkephalin) and Tyr-Gly-Gly-Phe-Leu (leucine enkephalin or [Leu<sup>5</sup>]enkephalin). It was soon shown that these pentapeptides were part of a larger polypeptide isolated from pituitary extracts (Cox et al., 1975; Teshemacher et al., 1975), ultimately leading to the discovery of and subsequent naming of the opioid active peptide  $\beta$ -endorphin. The larger polypeptide containing  $\beta$ -endorphin was isolated from pituitary extracts and shown to be  $\beta$ -lipotropin ( $\beta$ -LPH) which had been characterized by Li and co-workers (1965). The suggestion (Cox et al., 1976) that  $\beta$ -LPH, a pituitary hormone, with a 91 amino acid sequence was actually a prohormone that should have opioid activity in the  $\beta$ -LPH (61-91) fragment and no opioid

activity in the  $\beta$ -LPH (1-60) fragment was proposed for two reasons. Firstly, the methionine enkephalin pentapeptide isolated by Hughes and his co-workers (1975b) was contained within the  $\beta$ -LPH-(61-65) fragment, and secondly, residues 59 and 60 were Lys and Arg. It was known that in other prohormone systems a cleavage and removal of the Lys-Arg residues occurs on the carboxyl group side of the paired basic amino acids by a carboxypeptidase A mechanism. Another smaller polypeptide isolated from pituitary tissue (Cox et al., 1975; Lowney et al., 1979) had properties different from  $\beta$ -endorphin. It had a lower molecular weight than  $\beta$ -endorphin, was resistant to cyanogen bromide, and had a longer latency in reversal of its inhibitory effect on the GPI bioassay preparation. Further work on this smaller pituitary peptide (Goldstein et al., 1979) resulted in the purification and identification of the sequence of the first thirteen amino acids of what this group called dynorphin due to its potency in the MYD and GPI bioassay. Dynorphin (1-13) was later shown to have full potency of the subsequently characterized heptadecapeptide now known as dynorphin A. Conclusive evidence that these three major opioid peptide groups are independently processed was provided by the isolation of mRNA coding for each of the opioid peptide precursors. Pre-proopiomelanocortin (POMC) from which  $\beta$ -endorphin and adrenocorticotropin (ACTH) are derived was the first precursor to be described (Nakanishi et al., 1979). A mRNA that codes for the precursor of the enkephalins was characterized (Noda et al., 1982). A mRNA coding for porcine pre-prodynorphin has been described (Kakidani et al., 1982). Since the discovery of the enkephalins,  $\beta$ -endorphin, and dynorphin, many other opioid active peptides derived from the same precursors have been discovered. However, in many cases it remains to be demonstrated whether many of these peptides are selectively processed or are fragments of dynorphin or  $\beta$ -endorphin.

#### Heterogeneity of Opioid Receptors

The discovery of multiple endogenous opioid peptides led to the hypothesis that there



would be multiple receptors for these endogenous peptides. Heterogeneity of opioid receptors was first postulated on the basis of physiologic studies in the chronic spinal dog (Martin et al., 1976; Gilbert and Martin, 1976) and studies of opioid action in *in vivo* bioassay in GPI and MYD (Lord et al., 1977). The three opioid receptor types proposed by Martin and co-workers were mu ( $\mu$ ), the morphine selective site, kappa ( $\kappa$ ), the ketocyclazocine selective site, and sigma, the SKF-10047 selective site. An opioid receptor site in MYD that selectively bound leucine enkephalin and methionine enkephalin was described (Lord et al., 1977) and this group named this site the  $\delta$  receptor. This same receptor site was later identified by *in vitro* binding experiments using homogenates of MYD and [ $^3\text{H}$ -Tyr<sup>1</sup>-D-Ala<sup>2</sup>-D-Leu<sup>5</sup>]enkephalin ([ $^3\text{H}$ ]DADLE) a stable analog of [Leu<sup>5</sup>]enkephalin as a radioligand (Leslie et al., 1980). In addition, evidence for the epsilon ( $\epsilon$ ) opioid receptor site, a site that has a high affinity for [ $^3\text{H}$ ] $\beta$ -endorphin has been presented (Law et al., 1979; Ferrara and Li, 1980; Akil et al., 1980). Additional evidence for opioid receptor heterogeneity has been supplied by protection of receptor sites with a selective unlabelled ligand and alkylating unprotected sites with  $\beta$ -chloronaltrexamine (James and Goldstein, 1984). A further technique to study receptor heterogeneity is to utilize a radioligand that is partially selective for a preferred receptor type, in the presence of high concentrations of unlabelled ligands that are partially selective for the non-preferred receptor types (Gillan and Kosterlitz, 1982). The utilization of high concentrations of blocking drugs is applicable to binding assays but not to *in vivo* bioassay due to the blocking ligand producing opioid agonistic or antagonistic effects. In addition to the receptor sites discussed, subtypes of  $\mu$  and  $\kappa$  receptors have been proposed. Pasternak and co-workers have proposed  $\mu_1$  and  $\mu_2$  receptor subtypes based on *in vitro* binding assays which indicate heterogeneity of binding sites in biphasic Scatchard plots and complex displacement studies, as well as *in vivo* analgesia and toxicity tests. In these studies pretreatment of mice with naloxazone, an opiate receptor antagonist, resulted in loss of a high affinity site which represented 10 % of the total receptor sites for [ $^3\text{H}$ ]naloxone. The loss of these sites resulted in a marked reduction of morphine's analgesic potency, but not its lethal

effects. This would imply that the analgesic effects of morphine are mediated by the high affinity receptors that are lost with naloxazone treatment and that the lethal effects of morphine are mediated by the receptors that are resistant to naloxazone treatment. Evidence for the existence of  $k_1$  and  $k_2$  subtypes has been presented (Attali et al., 1982; Pfeiffer et al., 1981). Attali and co-workers (1982) utilized guinea pig lumbo-sacral spinal cord to study  $k$  subtypes. These authors were unable to identify  $\mu$  binding in guinea pig spinal cord using the radioligands [ $^3H$ ]DADLE or [ $^3H$ ]dihydromorphine. In this work  $k$ -subtypes were defined using [ $^3H$ ]ethylketocyclazocine ([ $^3H$ ]EKC) as the radioligand.  $k_1$  sites are proposed to be sites not blocked by 5  $\mu M$  [D-Ala<sup>2</sup>-Leu<sup>5</sup>]enkephalin (DADLE) while  $k_2$  sites are the sites labelled by [ $^3H$ ] EKC that are blocked by 5  $\mu M$  DADLE. The most potent ligand for the  $k_2$  sites described by Attali and co-workers was  $\beta$ -endorphin while benzomorphan drugs had a high affinity at the  $k_2$  site as well. However  $\beta$ -endorphin is not found in high concentrations in the spinal cord (Lewis et al., 1983) therefore it is unlikely that  $\beta$ -endorphin is the endogenous ligand for this receptor. Additional evidence for a benzomorphan site that may be a  $k$ -subtype is offered by Chang and co-workers (1981). The endogenous ligands for various opioid receptors are not clear in all cases. However, there is good evidence that "dynorphin" (1-17) is the endogenous ligand at the "k" type receptors (Cox and Chavkin, 1983). At this time the most probable endogenous ligands for the " $\delta$ " type receptor is "[Leu<sup>5</sup>]enkephalin" and "[Met<sup>5</sup>]enkephalin" (Lord et al., 1977; Cox et al., 1980). Recent evidence for an endogenous opioid that is immunoreactive with antibodies to morphine has been presented (Goldstein and Lowney, 1984). The possibility that this "newly discovered endogenous opioid substance" may be an endogenous ligand for the " $\mu$ " type receptor has not been thoroughly examined. The sigma opioid receptor may not be a classic opioid receptor. N-allylnorphenazocine (SKF-10047), a compound with psychotomimetic activity is a high affinity ligand for the sigma receptor. In addition SKF-10047 and cyclazocine displace [ $^3H$ ]phencyclidine with



high affinity (Quirion et al., 1981). Not all of the actions of SKF-10047 are naloxone reversible (Zukin and Zukin, 1984; Wood, P.L., 1981). The  $\epsilon$  receptor has not been well characterized at this time, therefore in this thesis only  $\mu$ ,  $\delta$  and  $\kappa$  opioid receptors will be considered further.

### Location of Opioid Receptors

Opioid receptors are predominantly associated with neural tissue. Opioid receptors found in tissue outside the central nervous system (CNS) have also been shown to be associated with neural tissue. Removal of the myenteric plexus from the guinea pig intestine resulted in a lack of any specific opioid receptor binding (Pert et al., 1973a). Analysis of opioid receptor binding in subcellular fractions of whole brain homogenates has shown opioid receptor binding in all fractions (Pert et al., 1974b). The crude mitochondrial fraction ( $P_2$ ) contained 50% of all binding and the second supernatant ( $S_2$ ) contained 17 % of all binding. Further subfractionation of  $P_2$  revealed significant binding in all fractions with highest levels located in synaptosomes. The high concentration of opioid receptors in synaptosomes suggests that opioid receptors are associated with areas of synaptic contact. Evidence that the synaptic pattern of enkephalin staining opioid terminals on thalamic projection neurons may have a functional organization was shown in recent work by Ruda and co-workers (1984). In this work thalamic projection neurons in lamina I of spinal cord receive immunoreactive enkephalin staining contacts on the soma or proximal dendrites of the neuron. Thalamic projection neurons that receive enkephalin contacts in lamina V of the spinal cord are multipolar cells that received enkephalin contacts on their distal dendrites.

### Regional Distribution of Opioid Receptors

Localization of opioid receptors within various sites in the CNS has been studied by four

primary techniques. Gross dissection of brain and analysis of opioid receptor density by *in vitro* receptor binding assays has been used extensively (Hiller et al., 1973). Another technique is the intravenous administration of tritium labelled opiate agonists or antagonists and separation of bound drug from total drug in the tissue by washing homogenates of selected brain regions (Pert et al., 1975). Some studies employ *in vivo* autoradiographic localization of opioid receptors in brain (Pert et al., 1976), or *in vitro* autoradiographic techniques (Goodman et al., 1980; Schubert et al., 1981). In addition, immunocytochemical techniques combined with electron microscopic analysis have been utilized to isolate opioid containing neurons (Hunt et al., 1980; Ruda, 1982; Ruda et al., 1984). All these techniques of investigation show that in the brain, opioid receptors are found in highest concentration in areas associated with the limbic system, but other brain systems also have high levels of opioid receptors. Brain locations that have shown a high concentration of opioid receptors are the periaqueductal grey, locus coeruleus, amygdala, caudate nucleus, substantia nigra and hypothalamus. At the spinal cord level, autoradiographic analysis (Lamotte et al., 1976) shows high levels of opioid receptors in laminae I, II and III. The use of immunohistochemical techniques (Hunt et al., 1980) showed high levels of enkephalin staining in laminae I and II of spinal cord. In addition, Ruda (1982) was able to show enkephalin staining synapses in lamina V of thalamic projection neurons. The variable distribution pattern of opioid receptors throughout the nervous system could indicate opioid regulation or modulation of neuronal processes associated with nociceptive, motor, sensory and endocrine functions.

The exact presynaptic or postsynaptic location of opioid receptors is an issue that is controversial in the literature. Evidence for presynaptic localization of opioid receptors on primary afferents comes from work by Lamotte and co-workers (1976). They were able to show that dorsal root rhizotomy resulted in a decrease in the concentration of opioid receptors in the spinal cord. Specific binding to dorsal roots of spinal cord was demonstrated by Fields and co-workers (1980). Other studies (Yaksh et al., 1980) showed that morphine inhibits the release of substance P from spinal cord. Substance P is one of the putative transmitters of

nociceptive impulses (Lembeck et al., 1981), and is located in primary afferents of spinal cord (Jessel et al., 1978). Demonstration of morphine's ability to inhibit the release of substance P from primary afferents is additional evidence for a presynaptic location of opioid receptors. Electrophysiological studies (Mudge et al., 1979) demonstrate enkephalin's ability to inhibit substance P release from sensory neurons in culture as well as to decrease the action potential of these neurons. In spite of all these lines of evidence for a presynaptic site for opioid receptors, morphologic support for a presynaptic location of opioid receptors has not been found at the ultrastructural level (Hunt et al., 1980; Sumal et al., 1982). The inability to identify enkephalin immunoreactive terminals forming synaptic contact with horseradish peroxidase labelled primary afferents in spinal cord is not conclusive evidence that presynaptic opioid receptors do not exist. Immunohistochemical studies (Hunt et al., 1980; Sumal et al., 1982) have utilized antibodies directed towards enkephalins. The crossreactivity of these antibodies with non-enkephalin opioid peptides is less than 2%. If dynorphin, a substance present in high concentrations in spinal cord (Bollicelli et al., 1981), was contained in presynaptic terminals of neurons that formed presynaptic contacts with primary afferents, it is unlikely that dynorphin containing terminals would have been recognized. An alternative explanation for loss of receptor binding after dorsal root rhizotomies without presynaptic changes at the ultrastructural level may be found in the recent work of Sugimoto and Gobel (1982) and Gobel (1984). These investigators have shown that removal of tooth pulp or cutting the distal radial nerve, damage which results in loss of the peripheral receptive fields of these sensory primary afferents, does not result in loss of axonal processes returning to the spinal cord. In addition, the axons of the primary afferents that have had their receptive fields removed show no morphologic change. However, primary sensory neurons that have had their peripheral receptive fields removed have been shown to become spontaneously active. Loss of peripheral receptive fields of sensory neurons does result in cavitation and eventual involution of dendritic processes of second order neurons in laminae I and II of the spinal cord. This type of damage in second order neurons certainly



would result in loss of opioid receptors from these dendrites. This damage may result from excessive release of transmitter from the primary afferents or loss of transportable proteins from primary afferents. However, Gobel (1984) states that dorsal root rhizotomy with short or long term survival times failed to produce the changes seen with peripheral non-lethal damage to sensory primary afferents. It may be possible that dorsal root rhizotomy doesn't produce morphologic changes visible at the electron microscopic level but may produce functional changes in second order neurons which results in loss of opioid receptor binding. These findings may have clinical relevance in providing a greater insight into the mechanism of chronic pain disorders such as phantom limb sensations and causalgias.

#### Ionic Effects On Opioid Binding

Early work showed opioid binding was regulated by monovalent and divalent cations (Pert and Snyder, 1974; Simon et al., 1973; Pasternak et al., 1975). Divalent cations have their greatest effects on modulation of opioid binding regulation by guanine nucleotides (GTP) (Childers and Snyder, 1980). Manganese was most active in decreasing the inhibitory effects of GTP on opioid binding to receptors. However, the concentration necessary for this effect is higher than the concentration present in normal neurons. Magnesium, an ion present in physiologic fluids, at a concentration that is effective in decreasing the inhibitory effects of GTP on opioid binding may have effects similar to manganese (Chang et al., 1983). Manganese has a greater effect of increasing opiate agonist binding in the presence of sodium while little effect on binding of opiate antagonists in the presence or absence of sodium is noted (Pasternak et al., 1975). Recent studies (Cox et al., 1984; Werling et al., 1984b) varied the ionic composition of the buffer, but maintained a constant ionic strength by replacing  $\text{Na}^+$  with  $\text{K}^+$ . The replacement of  $\text{Na}^+$  by  $\text{K}^+$  resulted in a 2 fold increase in affinity of  $[^3\text{H}]\text{EKC}$  at  $\kappa$  sites, a 2.8 fold increase in affinity of  $[^3\text{H}]\text{DAGO}$  at  $\mu$  sites and a 1.2 fold increase in affinity of  $[^3\text{H}]\text{DADLE}$  at  $\delta$  sites. The  $B_{\text{MAX}}$  of  $\delta$  sites increased when  $\text{Na}^+$  was replaced by  $\text{K}^+$ . This effect

was not seen with  $\mu$  and  $\kappa$  sites. The exact site of  $\text{Na}^+$  regulation is uncertain; however, from these recent studies an intracellular site of  $\text{Na}^+$  regulation may be suggested by the low concentrations of  $\text{Na}^+$  necessary to decrease the affinity of [ $^3\text{H}$ ]DADLE binding.

#### Effects of GTP On Opioid Receptor Binding

The effects of GTP on opioid receptor binding are variable depending upon the ionic composition of the buffer medium in which the binding assay is conducted. Childers and Snyder (1978 and 1982) reported that in rat brain homogenates GTP or GDP reduced the binding affinity of opioid agonists and to a lesser extent decreased the binding affinities of antagonists as well. However, in the presence of sodium, GTP and GDP decreased the binding affinities of opioid agonists but not of opioid antagonists. Chang and co-workers reported that GTP, GDP and non-hydrolyzable analogs reduced binding of [ $^3\text{H}$ ]DADLE to isolated  $\mu$  and  $\delta$  receptors. The inhibitory effect was increased by addition of sodium to the incubation medium, and the inhibitory effects of GTP or GDP and sodium could be reversed by  $\text{Mg}^{2+}$ . The inhibitory effects of GTP analogs could not be reversed by addition of  $\text{Mg}^{2+}$ . The increase in high affinity sites and the reversal of inhibitory effects of GTP and GDP on opioid binding by  $\text{Mg}^{2+}$  are proposed to be due to increased hydrolysis of GDP or GTP and dissociation from the receptor (Chang et al., 1983). Recent work by Werling and co-workers (1984b) has shown GTP reduces binding affinities significantly at both isolated  $\mu$  and  $\delta$  sites with a smaller reduction in the affinity for binding at  $\kappa$  sites, possibly indicating that fewer  $\kappa$  receptor sites are regulated by GTP. The significance of GTP regulation of opioid binding is not totally clear at this time. GTP effects on opioid receptor binding may help to explain the marked difference between the opioid receptor affinities measured *in vitro* and the effective concentrations of opioid agonists necessary to produce physiologic effects *in vitro* (Cox et al., 1984). The variable effects of GTP, sodium and manganese on the binding of opioid agonists or antagonists may be utilized in *in vitro* binding assays to determine if the binding of an agonist/antagonist



opiate analgesic at an isolated opioid receptor site is consistent with binding of an agonist or an antagonist to each isolated opioid receptor site.

#### Transduction of Opioid Receptor Occupation

The initial effect of activation of opioid receptors by an opiate or opioid agonist is unclear at this time. Studies of the effects of opiates on neuroblastoma X glioma (NG-108-15) hybrid cells have demonstrated that opioid receptors of the  $\delta$  type mediate inhibitory effects on adenylate cyclase in whole cells (Sharma et al., 1975) or homogenates of NG-108-15 hybrid cells (Blume et al., 1979). In addition, the initial report that adenylate cyclase is inhibited in homogenates of mammalian brain (Collier and Roy, 1974) has recently been verified using homogenates of rat striatal membrane homogenates (Law et al., 1981; Cooper et al., 1982). Blume and co-workers (1979) have noted that GTP and  $\text{Na}^+$  are required in the assay in order to be able to measure opiate inhibition of adenylate cyclase. Koski and Klee (1981) have shown that opiates increase GTPase activity in NG-108-15 cells. Barchfeld and Medzihradsky (1984) have shown that opiates also stimulate GTPase activity in rat striatal membranes. Increasing GTPase activity may have a role in a reduction of the GTP concentrations necessary for the activation of adenylate cyclase, which then results in a reduction of cyclic AMP (cAMP). However, opiate induced increase in GTPase activity may not be the primary mechanism for opiate inhibition of adenylate cyclase. GTP analogues can function as a substitute for GTP and in the absence of opiates produce inhibition of adenylate cyclase (Frey and Kebabian 1984). Work by Frey and Kebabian (1984) using a PRL-secreting 7315c tumor cell further clarifies the mechanism of opiate inhibition of adenylate cyclase. This 7315c tumor cell has an opioid receptor with apparent  $\mu$  characteristics. In addition, this tumor cell has two guanyl nucleotide regulatory proteins designated  $\text{N}_i$  for the inhibitory protein and  $\text{N}_s$  for the stimulatory protein. These workers suggest that the  $\mu$  opiate receptor may be coupled to  $\text{N}_i$ . The binding of an opiate to the  $\mu$  opiate

receptor in this system in the presence of GTP is proposed to result in the binding of GTP to  $N_1$  which results in the inhibition of adenylate cyclase. Binding of an opiate agonist to the  $\mu$  opiate receptor in this system increases the binding of GTP to  $N_1$  as well as hydrolysis of GTP to GDP. However, this GTPase activity of  $N_1$  is the result of opiate binding to the  $\mu$  opiate receptor site and is not a necessary component of inhibition of adenylate cyclase since GTP analogs resistant to hydrolysis can substitute for GTP in this system.

The electrophysiologic effects of opiates are receptor specific. The  $\mu$  agonist normorphine and the  $\delta$  agonist DADLE have been shown to increase the  $K^+$  conductance of small interneurons in the substantia gelatinosa of rat spinal cord (Yoshimura and North, 1983). Werz and MacDonald (1984) have shown that in mouse dorsal root ganglion neurons  $\mu$  and  $\delta$  agonists increase  $K^+$  conductance. However, dynorphin which acts at  $\kappa$  receptors blocks voltage dependent calcium entry into the neuron (Werz and MacDonald, 1984). The increased  $K^+$  conductance produced by  $\mu$  and  $\delta$  agonists is blocked by cesium ( $K^+$  channel blocker), while the decreased calcium conductance produced by dynorphin is unaffected by cesium application. The hyperpolarizing effect of the increased  $K^+$  conductance could inhibit depolarization and the entry of calcium into the neuron thereby inhibiting transmitter release. Therefore  $\mu$ ,  $\delta$ , and  $\kappa$  opiate and opioid ligand receptor binding could serve to block transmitter release. Moreover, the effects of  $\mu$  and  $\delta$  ligands could be additive to the effects of  $\kappa$  ligands on calcium channels. It is unclear if the electrophysiologic effects of opioid receptor binding are primary effects or secondary to reductions in cAMP. Kandel and Schwarz (1982) have proposed a model where a cAMP dependent protein kinase is responsible for phosphorylation of a  $K^+$  channel protein that results in decreased  $K^+$  conductance out of the cell. When the levels of cAMP are decreased by opiates there could be a reduction of the phosphorylation of the  $K^+$  channel protein and a resulting increase in the  $K^+$  conductance out of the cell. This model is consistent with the electrophysiologic changes induced by opiates in neural tissue. A possible mechanism for the effects of  $\mu$  and  $\delta$  opioid agonist binding could be that receptor occupation results in an

increase in GTP binding by  $N_1$  which would inhibit adenylate cyclase and produce a reduction in cAMP levels. The reduction of cAMP results in decreased activity of the cAMP dependent protein kinase, and reduced phosphorylation of membrane proteins which results in an increase of  $K^+$  conductance causing hyperpolarization and decreased calcium entry into the neuron via a voltage dependent calcium channel. The mechanism for  $\kappa$  agonist receptor binding could be the reduced cAMP levels producing a reduction of phosphorylation of membrane proteins associated with a calcium channel and a resulting reduction of calcium entry into the neuron. However, evidence for  $\kappa$  opioid receptor activation producing a reduction in adenylate cyclase activity and cAMP has not yet been described. It is not certain at this time if the changes in adenylate cyclase activity by opiates is the primary mechanism for reducing transmitter release from neurones. However, it is well known that opioid receptor binding of agonists results in decreased transmitter release from neurones in a number of systems. Inhibition of acetylcholine release from guinea pig myenteric plexus has been shown (Paton, 1957; Cox and Weinstock, 1966). Morphine has been shown to inhibit norepinephrine release in mouse vas deferens (Henderson et al., 1972). Inhibition of norepinephrine release from cerebral cortex due to receptor binding of opiate drugs has been reported most recently by Hagan and Hughes (1984).

#### Intrathecal and Epidural Opiate Analgesia

The idea for the use of intrathecal and epidural opiate injections for selective analgesia evolved from the work of four groups. The initial discovery of immunoreactive leucine enkephalin in laminae I and II of spinal cord (Elde et al., 1976), indicated that endogenous opioids could have a role in modulation of nociceptive input to higher brain centers. Lamotte and co-workers (1976) showed that dorsal root rhizotomy decreased opiate receptor binding in spinal cord. Work by Jessell and Iversen (1978) showed capsaicin produced a depletion of substance P from small diameter primary afferent C-type fibers. Mudge and co-workers



(1979), using cell culture, and Yaksh and co-workers (1980), using *in vivo* studies, were able to show decreased release of substance P from primary afferents after administration of enkephalin or morphine. This set of observations implied that substance P is the transmitter of nociceptive input from primary afferent C-type fibers to the dorsal horn of spinal cord and that morphine or opioid peptides acting via opioid receptors located pre- or postsynaptically can modulate nociceptive input by inhibiting the release of substance P. Yaksh and Rudy (1976a) developed a technique for chronic cannulation of the intrathecal space and were able to show analgesia mediated by a direct spinal action of opiates in animals (Yaksh and Rudy, 1976b). Further work by Yaksh (1978) showed that the analgesia from intrathecal opiates had a somatotopic distribution, with the cord dermatomes nearest the catheter tip the earliest to be affected. In no case did the analgesia extend above the shoulders, implying that the analgesia was due to opioid receptor occupation at the spinal cord level and not to activation of descending pathways to the dorsal horn of spinal cord. The use of intrathecal morphine for analgesia in man was first utilized by J.K. Wang (1977). Later Wang and co-workers reported on the use of intrathecal morphine to relieve severe intractable pain in lower back and legs secondary to malignancies of the genitourinary tract. The analgesia achieved with intrathecal opiates in man or animals is not associated with any motor or autonomic impairment. Likewise, sensation to temperature and light touch are unaffected. Since the early use of intrathecal opiates by Wang, the use of intrathecal or epidural (extradural) opiates has appeared in a variety of clinical settings. Epidural and intrathecal opiates have been utilized for relief of post-operative pain from upper and lower abdominal procedures (Bromage et al., 1980; Behar et al., 1979; Cousins et al., 1979), postoperative thoracotomies (Magora et al., 1980), and for analgesia during labor and delivery (Scott and McClure, 1979). The concentrations of opiate utilized in these studies were from 0.5 - 3 mg morphine, or 10 - 30 mg meperidine, which resulted in analgesia from 12 - 24 hrs. As noted earlier, the site of action of intrathecal or epidural opiate administration is proposed to be at the spinal cord level.

To further investigate the site of action of intrathecally administered opiates, Wood and co-workers (1981) studied the effects of EKC and morphine in the chronic spinal animal. EKC had a marked analgesic activity when administered intrathecally but not when administered to the periaqueductal gray (PAQ). Morphine had a greater analgesic effect when injected to the PAQ than when injected to the intrathecal space. The ability of EKC to produce analgesia in the chronic spinal animal without any central effect is taken as evidence by these workers that the actions of EKC are due to direct effects at the spinal cord level. However, if the dose of opiate administered to the intrathecal or epidural space is high enough to allow for absorption and redistribution to the systemic circulation or for rostral redistribution to higher brain centers, then analgesia will be mediated at the cord level as well as by activation of descending analgesia pathways to the dorsal horn of spinal cord. The central endogenous descending analgesic pathways are thought to consist of opioid receptor activated excitatory neuronal projections from the PAQ to descending serotonergic neurons that have their origin in the nucleus reticularis magnocellularis, medullary nucleus raphe magnus, and dorsal nucleus reticularis gigantocellularis. These serotonergic neurons form synaptic contacts with immunoreactive enkephalin containing interneurons in laminae I and II of dorsal horn of spinal cord (Basbaum and Fields, 1978). In addition, the medullary nucleus raphe magnus sends excitatory projections to the locus coeruleus, which in turn sends descending excitatory noradrenergic projections to small immunoreactive enkephalin containing interneurons in laminae I and II of the dorsal spinal cord (Gobel et al., 1980). The descending serotonergic and noradrenergic synaptic contacts with immunoreactive enkephalin interneurons have been shown to take up [ $^3$ H]serotonin (Ruda and Gobel, 1980) and [ $^3$ H]norepinephrine (Ruda et al., 1979). Activation of the serotonergic and noradrenergic synaptic contacts in laminae I and II of the dorsal horn of spinal cord may provide an additional mechanism to increase analgesia at the spinal cord level. Yaksh (1979) showed that intrathecal administration of serotonin or norepinephrine produced analgesia similar to that seen with stimulation of the descending serotonergic and noradrenergic pathways by the application of opiates to the PAQ. In addition,



intrathecal administration of methysergide and phentolamine significantly reversed the analgesia seen with opiate administration to the PAG.

The opioid receptor sites in the spinal cord that are responsible for antinociception are not totally clear at this time. The work of Martin and co-workers (1976) established evidence for  $\mu$ ,  $\kappa$  and sigma receptors in spinal cord as well as brain based on pharmacologic studies. Further evidence of receptor heterogeneity in spinal cord has been established by radioligand binding studies. Previous radioligand binding studies in spinal cord from various species have all been carried out in Tris HCl buffer at a wide variety of temperatures from 4°C to 37°C (Kelly et al., 1980; Czlonkowski et al., 1983; Mack et al., 1984; Attali et al., 1982; Gouarderes et al., 1982). Opioid receptor heterogeneity with binding sites that have  $\mu$ ,  $\delta$  and  $\kappa$  characteristics have been identified in human, rat and guinea pig spinal cord (Czlonkowski et al., 1983) and rat spinal cord (Mack et al., 1984). However, the total reported receptor densities as well as the ratios of receptor subtypes vary widely even within the same species. Czlonkowski and co-workers (1983) showed that postmortem whole human spinal cord had a total opiate receptor density of 22 fmols/mg protein and rat lumbo-sacral spinal cord had a total density of 8 fmol/mg protein. Mack and co-workers found that whole rat spinal cord had a total opiate receptor density of 143 fmol/mg protein. Two research groups working with rat lumbo-sacral spinal cord (Gouarderes et al., 1982) and guinea pig lumbo-sacral spinal cord (Attali et al., 1982) have claimed absence of any specific  $\mu$  or  $\delta$  binding in these tissues based upon the lack of specific binding of [ $^3$ H]dihydromorphine, [ $^3$ H]morphine, or [ $^3$ H]DADLE. The apparent absence of  $\mu$  or  $\delta$  binding in rat or guinea pig lumbo-sacral spinal cord prompted Gouarderes and co-workers (1982) to believe that all specific opioid receptor binding in rat lumbo-sacral spinal cord was of a  $\kappa$  receptor type. However, the low affinity of DADLE and morphine at this site in rat lumbo-sacral spinal cord lead Gouarderes to conclude that all specific binding of [ $^3$ H]EKC and [ $^3$ H]etorphine in rat lumbo-sacral spinal cord was to a benzomorphan binding site similar to a site characterized

by other workers in mouse brain homogenates (Chang et al., 1981). Attali and co-workers proposed the existence of two  $\kappa$  receptor types in guinea pig lumbo-sacral spinal cord on the basis of the absence of observed  $\mu$  or  $\delta$  binding and the differential effects of a 5  $\mu$ M DADLE block on [ $^3$ H]EKC and [ $^3$ H]etorphine binding. When 5  $\mu$ M DADLE block was added to the binding assay there was a loss of a component of the high affinity binding of [ $^3$ H]EKC and no change in the low affinity binding of [ $^3$ H]EKC and loss of specific binding for [ $^3$ H]etorphine. The portion of the high affinity binding of [ $^3$ H]EKC that was lost was identified as the DADLE sensitive site ( $DAL_5$ ) and the high affinity binding of [ $^3$ H]EKC that remained was identified as the DADLE insensitive site ( $DAL_1$ ). The  $DAL_1$  site was proposed to be a  $\kappa$  opioid receptor of the type previously described by Kosterlitz and co-workers (1981). The  $DAL_5$  site was proposed to be a benzomorphan site. The absence of  $\mu$  or  $\delta$  binding in lumbo-sacral spinal cord (Attali et al., 1982; Gouarderes et al., 1982) is difficult to resolve since morphine and DADLE administered intrathecally to rats produce analgesia with a somatotopic distribution that can be selectively limited to the lumbo-sacral spinal cord segments (Yaksh, 1984). In addition, animals rendered tolerant to intrathecal morphine do not show cross-tolerance to intrathecal injections of DADLE. However, there is an asymmetric cross-tolerance to morphine in animals rendered tolerant to intrathecal injections of DADLE (Yaksh, 1984). These pharmacologic findings are consistent with morphine producing tolerance at  $\mu$  receptors but not at  $\delta$  receptors. DADLE, an opioid agonist with affinity for both  $\mu$  and  $\delta$  receptors (Werling et al., 1984a) produces tolerance at both  $\mu$  and  $\delta$  receptors. This type of *in vivo* pharmacologic evidence strongly supports the existence of  $\mu$  and  $\delta$  opioid receptors in lumbo-sacral spinal cord.

It was the purpose of this study to attempt to quantify  $\mu$ ,  $\delta$ , and  $\kappa$  type opioid receptors in guinea pig whole spinal cord under conditions of physiologic temperature and cation concentrations. It has been shown early in the introduction of this thesis that sodium and other major physiologic cations as well as temperature have significant effects on radioligand

binding. Therefore we feel it is important to characterize opioid receptor binding in this tissue under conditions close to physiological conditions. Due to the difficulties associated with maintaining a stable pH using bicarbonate buffers in a binding assay 25 mM HEPES buffer was substituted for bicarbonate in this system. In addition, DAGO, a  $\mu$  site selective ligand (Kosterlitz et al., 1981), has been utilized to identify  $\mu$  receptor sites in guinea pig lumbo-sacral spinal cord. Severe delayed respiratory depression is a rare but potentially fatal complication of intrathecal or epidural opiate analgesia that has only been reported in postoperative patients (Yaksh, 1981). It is because of this complication that nalbuphine HCl, an opiate agonist antagonist analgesic with a ceiling effect on respiratory depression equal to 30 mg of morphine, (Romagnoli and Keats, 1980) and morphine have been included in this study. Nalbuphine HCl given intrathecally to rats produces analgesia when the intraperitoneal acetic acid writhing test is used to measure analgesia. Nalbuphine is not an effective analgesic when fast pain tests such as the paw press or shock titration test are used to measure analgesia (Schmauss et al., 1983). Co-administration of low doses of morphine and nalbuphine intrathecally produce analgesia equal to that seen with high doses of morphine when the acetic acid writhing test is employed. Co-administration of high doses of morphine and nalbuphine results in a marked reduction in the analgesia seen with co-administration of low doses of nalbuphine and morphine. Nalbuphine HCl is one of the few agonist antagonist opiate analgesics that has been found to have a significant intrathecal analgesic effect. Knowledge of nalbuphine's affinity at isolated spinal cord opioid receptor types may help to understand this compound's intrathecal analgesic activity *in vivo*.



## Materials.

[<sup>3</sup>H]Ethylketocyclazocine ([<sup>3</sup>H]EKC) 19.9 Ci/mmole, was purchased from New England Nuclear Corporation (Boston, MA.). [<sup>3</sup>H-Tyr<sup>1</sup>-D-Ala<sup>2</sup>-MePhe<sup>4</sup>-Glyoi<sup>5</sup>]enkephalin ([<sup>3</sup>H]DA60), 60 Ci/mmole, was purchased from Amersham Corporation (Arlington Heights, IL). [<sup>3</sup>H-Tyr<sup>1</sup>-D-Ala<sup>2</sup>-D-Leu<sup>5</sup>]enkephalin ([<sup>3</sup>H]DADLE), 36.5 Ci/mmole, was purchased from Amersham Corporation (Arlington Heights, IL). [D-Ala<sup>2</sup>-MePhe<sup>4</sup>-Glyoi<sup>5</sup>]enkephalin (DA60) was purchased from Cambridge Research Biochemicals LTD. (Beach NY). [D-Ser<sup>2</sup>-Leu<sup>5</sup>]enkephalin Thr<sup>6</sup> (DSTLE) was purchased from Sigma Chemical Company (St. Louis, MO). Ethylketocyclazocine methane sulfonate (EKC) was supplied by Sterling Winthrop Labs (Rensselaer, NY), naloxone hydrochloride from Endo Labs. (Garden City, NY), and U50488H was a gift from Upjohn Labs. The following ligands were generous gifts: morphine sulfate, Dr. L. Aronow; nalbuphine hydrochloride Dr. S. Muldoon, and WIN 44,401-2 as well as WIN 44,401-3 Dr. A.I. Faden. HEPES and HEPES NaCl were purchased from Sigma Chemical Corp. (St. Louis, MO). Fresh dilutions of drugs were prepared for each experiment and 25mM HEPES salt buffer was used to dilute stock drugs.

## Methods

### Preparation of Spinal Cord Membranes

The method of guinea pig brain membrane preparation (Dunlap et al., 1979) was modified in the following manner for spinal cord membrane preparation. Male Hartley guinea pigs (400-500 gm) were purchased from Controlled Animal Management and Marketing (Wayne, NJ). Guinea pigs were killed by decapitation, the vertebral column was dissected in block, divided into four segments, and placed on ice. Spinal cord segments were rapidly removed from each vertebral column segment by application of a high pressure air line to the distal end. Spinal cord segments removed in this manner were rapidly placed in ice-cold HEPES salt buffer (25 mM HEPES, 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgCl<sub>2</sub>, 2.4 mM CaCl<sub>2</sub>, pH adjusted to 7.4).



Tissue from 4-6 animals was pooled, weighed, and 10 volumes of HEPES salt buffer was added to the wet weight of the tissue. Tissue was homogenized using a teflon glass homogenizer from Thomas Scientific (Philadelphia, PA) driven by a T-Line laboratory stirrer (Emerson, NY) setting of 70, using ten full strokes. The crude membrane homogenate was divided into 10-15 ml portions, placed into 50 ml centrifuge tubes, and centrifuged at  $27,000 \times g$  for 15 min at  $4^{\circ}\text{C}$  in a Sorvall RC-5B refrigerated centrifuge made by Dupont Instruments (Newton, CT). The supernatant was discarded and the pellet resuspended in 20 volumes of HEPES salt buffer with a Vortex mixer and incubated at  $0^{\circ}\text{C}$  for 60 min to remove any endogenous ligand. At the end of 60 min, the membrane suspension was centrifuged at  $27,000 \times g$  for 15 min at  $4^{\circ}\text{C}$ . The resulting supernatant was discarded, and the pellet was resuspended in 10 volumes of HEPES salt buffer. After 2 additional centrifugation steps at  $27,000 \times g$  for 15 min at  $4^{\circ}\text{C}$ , discarding the supernatant, and resuspending the residual pellet in ten volumes of HEPES salt buffer, the final pellet was resuspended to a concentration of 2% w/v in 25 mM HEPES salt buffer and frozen at  $-70^{\circ}\text{C}$  for not more than three weeks prior to use in receptor binding assays. In seven independent membrane preparations, the protein content ranged from 290-320  $\mu\text{g}$  protein/250  $\mu\text{l}$  membrane suspension. There was no significant differences ( $P > 0.05$ ) between the mean protein contents of each membrane preparation when compared using post-hoc Scheffe analysis. Therefore the grand mean of 300  $\mu\text{g}$  protein/250  $\mu\text{l}$  membrane suspension was used to adjust all  $B_{\text{MAX}}$  values to  $B_{\text{MAX}}$  in pmols/mg protein.

#### Protein Assay

Protein concentrations were determined by a modification of the Lowry procedure (Peterson, 1977). This technique includes a precipitation step with 0.1 ml of 0.15% sodium deoxycholate (DOC) and 0.1 ml of 72% trichloroacetic acid (TCA), and employs bovine serum albumin as standard.

## Measurement of Radioligand Binding

Radioligand binding techniques of Dunlap et al., (1979) were modified as follows for this series of experiments. Aliquots of spinal cord membrane suspension were incubated at a final concentration of 1% (W/V) and in a final volume adjusted to 500  $\mu$ l with 25 mM HEPES salt buffer in 12 X 75 mm disposable plastic test tubes from Chase Instruments Corp. (Poultney, VT). Displacing drugs or blocking drugs were added in volumes of 50  $\mu$ l. The reaction was started by adding 100  $\mu$ l radiolabelled drug to samples after both the radiolabelled drug and the triplicate samples were prewarmed for 5 min to assure a 37°C temperature for the entire incubation period. Tubes were incubated an additional 20 min in a Dubnoff metabolic shaking unit from Precision Scientific Group (Chicago, IL). The incubation was terminated by addition of 4 ml ice-cold 25 mM HEPES salt buffer to the incubation tube and filtered through #32 Glass Fiber Fillers from Schleicher and Schuell Inc. (Keene, NH) in an Amicon 12 position filter box (Amicon, Lexington, MA) followed by 2 additional 4 ml washes per filter. Total termination time for each incubation tube was less than 15 seconds. After filtration, filters were placed in 20 ml plastic scintillation vials and soaked in 1 ml of 100% ethanol overnight. Radioactivity retained on the filters was measured by liquid scintillation counting after addition of 8 ml of Ready-Solv EP (Beckman Instruments Inc., Fullerton CA). The samples were counted for 5 min at an efficiency of about 39% in a Beckman LS 7800 Liquid Scintillation Counter (Beckman Instruments Inc., Irvine, CA). Specific binding was determined by subtracting from total binding the amount of binding that remained when 1  $\mu$ M final concentration of the appropriate unlabelled drug was added to the incubation triplicates (non-specific binding). For [ $^3$ H]EKC experiments nonspecific binding was measured by inclusion of unlabelled EKC, for [ $^3$ H]DADLE, DSTLE, and for [ $^3$ H]DAGO experiments, unlabelled DAGO was added to incubation triplicates. When 1  $\mu$ M naloxone was included in assay to measure non-specific binding there was no significant difference in the level of non-specific binding measured by naloxone or the previously mentioned unlabelled compounds. Pseudo first order conditions were assumed, i.e.

that radioligand concentration was much higher than receptor concentration. This was a valid assumption since in our experiments specific binding of guinea pig spinal cord membrane suspension was always less than 4% of the total added radiolabelled drug. In addition, saturation binding experiments were performed to establish the  $K_D$  of the radioligand to allow displacement studies of the radiolabelled compound with unlabelled ligands below the  $K_D$  of the radiolabel at its high affinity site. This allowed the use of the Cheng /Prusoff formula (Cheng and Prusoff, 1973) to calculate an inhibition constant for the unlabelled ligand as follows:  $K_I = IC_{50} / 1 + [L] / K_D$  where  $K_D$  is the  $K_D$  of the radiolabel and  $[L]$  is the concentration of the radiolabel. This formula allows for normalization of various displacement  $IC_{50}$ 's from displacement studies performed at various concentrations of radiolabelled ligand. Inhibition constants ( $K_I$ 's) derived by this formula are comparable to  $K_D$ 's derived from saturation curve experiments.

#### Stability Check of Radioligands

Radioligands were incubated with 25 mM HEPES salt buffer or guinea pig spinal cord membrane suspension for 60 min at 37°C. TLC of radiolabelled ligands was performed using techniques described by (Leslie et al., 1980) except where otherwise noted. After incubation, reaction tubes were placed on ice, 500 µl of 1-butanol added to each tube. The tubes were mixed by inversion, and centrifuged at 4°C and 5,000 x g for 15 min. This butanol extraction step was included to separate the drug from the salts and membranes, which we had previously found to interfere with the migration of the drug on the TLC. The upper 400 µl of the butanol phase was aspirated from each reaction tube and placed in fresh 12 X 75 mm test tubes and dried under a nitrogen dryer, 30 µl of methanol was added to each tube to allow spotting of the extracted radiolabel on chromatogram sheets. Eastman Silica Gel Chromagram sheets 20 X 20 cm sheets (Eastman Kodak Comp., Rodchester, NY) were divided into 5 cm strips and each of these portions



marked into three TLC lanes. In lane 1, authentic drug in distilled water was spotted, in lane 2, drug incubated with HEPES salt buffer was spotted, and in lane 3, drug incubated with spinal cord membrane suspension was spotted. TLC strips spotted with [ $^3\text{H}$ ]EKC were developed in a mixture of  $\text{CHCl}_3$ - $\text{CH}_3\text{OH}$ -28%  $\text{NH}_4\text{OH}$  (6 ml:4 ml:1 drop). [ $^3\text{H}$ ]DAGO or [ $^3\text{H}$ ]DADLE TLC sheets were developed in a mixture of  $\text{CHCl}_3$ - $\text{CH}_3\text{OH}$ - $\text{CH}_3\text{COOH}$ - $\text{H}_2\text{O}$  (10:10:2:3). The TLC strip was cut horizontally into 0.5 cm bands starting 0.25 cm before the origin and ending 0.25 cm after the solvent front, placed in 20 ml plastic liquid scintillation vials, 1 ml of 100% ethanol and 8 ml of Beckman Ready-Solv EP liquid scintillation fluid added, and vials counted at an efficiency of approximately 39%.

#### Stability Determination of Unlabelled Ligands

Stability of the unlabelled ligands was assessed by extending the assay incubation time of 20 min to 60 min at  $37^\circ\text{C}$ . Preincubation with displacer was extended to 45 min. Labelled compound was then added to the incubation mixture and incubation continued for an additional 20 min. The reaction was terminated as described in the "Measurement of Radiolabel Binding" section. Specific binding to membranes with incubation times of 20 min and 60 min with the same concentration of cold displacer were compared. If significant degradation of unlabelled displacing ligand had occurred, inhibition of specific binding at 60 min would be less than after 20 min incubation.



## Results

### TLC of Radiolabelled Ligands

Recovery of [ $^3\text{H}$ ]EKC, [ $^3\text{H}$ ]DAGO, and [ $^3\text{H}$ ]DADLE, from 1-butanol and aqueous phases were 84%, 91%, and 91% respectively. All the radiolabelled compounds used in these experiments showed preferential affinity for the butanol phase with the following butanol/HEPES salt buffer partition coefficients: [ $^3\text{H}$ ]EKC, 123; [ $^3\text{H}$ ]DAGO, 2.2; and [ $^3\text{H}$ ]DADLE, 4.4. Both [ $^3\text{H}$ ]DAGO and [ $^3\text{H}$ ]DADLE incubated in the presence of salt buffer as well as in the presence of membrane suspension displayed the same pattern of migration as authentic drug spotted directly onto the chromatogram (Fig. 1). The TLC pattern for [ $^3\text{H}$ ]EKC incubated with HEPES salt buffer or guinea pig spinal cord membrane suspension showed a distinctive peak that migrated the same distance as the unincubated drug peak (Fig. 2). However, in both cases the TLC pattern showed two additional small peaks. The additional small peaks could be due to salt from buffer partitioning into the butanol phase during the extraction step and inhibiting normal [ $^3\text{H}$ ]EKC migration pattern on TLC sheets.



### Stability of Unlabelled Compounds

In comparing the amount of displacement of specific binding at 20 and 60 min time points for all unlabelled drugs used in these experiments, 90–97% of all displacement seen at 20 min was still present at 60 min. These findings were taken as evidence that unlabelled compounds were stable under our assay conditions.

### Characterization of Specific Binding of Labelled Ligands

To maintain all binding conditions as close to physiologic conditions as possible all binding assays were carried out at 37°C, pH 7.4, and using HEPES salt buffer. The kinetic properties of radiolabelled ligand binding in guinea pig spinal cord membranes was tested for

FIGURE 1. TLC OF [ $^3\text{H}$ ]DADLE (A) AND [ $^3\text{H}$ ]DAGO (B). TLC carried out as described in Methods section, control drug ( $\Delta$ ), drug incubated with HEPES salt buffer ( $\square$ ), drug incubated with guinea pig spinal cord membranes in HEPES salt buffer (O). N = 1.






FIGURE 2. TLC OF [<sup>3</sup>H]EKC. TLC carried out as described in methods section. Control drug (Δ), drug incubated with HEPES salt buffer (■), drug incubated with spinal cord membranes in HEPES salt buffer (●). N = 2.





all ligands used in this study by doing both time course of association and dissociation experiments. A plateau of specific binding was reached within the first five min and showed a slight increase over the next fifteen min (Fig 3a.). Specific binding was at equilibrium 20 min after the reaction was started. For all further experiments assay tubes were incubated with labelled compound for 20 min. Dissociation time curve experiments were carried out for all radioligands by addition of 12 ml ice-cold HEPES salt buffer. Due to a shortage of guinea pig spinal cord tissue guinea pig cerebral cortex was used for dissociation experiments. The dissociation  $t_{1/2}$  time for [ $^3\text{H}$ ]EKC was 19 min (Fig. 3b.). In comparable experiments for [ $^3\text{H}$ ]DAGO and [ $^3\text{H}$ ]DADLE, 70 % of specific control binding of both [ $^3\text{H}$ ]DAGO and [ $^3\text{H}$ ]DADLE remained bound to membranes after 10 min dissociation in ice-cold buffer. This dissociation rate was not a hindrance to measurement of maximum specific binding or  $B_{\text{MAX}}$ , since reaction tubes were filtered rapidly in a time span of approximately 15 sec. Specific binding was linear for all three radioligands with membrane protein over a range of approximately 150–650  $\mu\text{g}$  protein (Fig 4). As noted under Methods section 300  $\mu\text{g}$  protein in a total volume of 500  $\mu\text{l}$  was added to each reaction tube, thus insuring that all measurements of binding were made in the region of linearity of protein concentration versus binding. Maintaining the membrane suspension, salt buffer, and unlabelled ligands on ice for 1–2 hr prior to use had no effect on specific binding.

#### Characterization of Specific Binding of [ $^3\text{H}$ ]DAGO

Specific binding was found to be saturable when membrane suspension was incubated with increasing concentrations of [ $^3\text{H}$ ]DAGO (Fig. 5a.). Increasing concentrations of [ $^3\text{H}$ ]DAGO were added up to 10 nM. Higher concentrations were achieved by adding non-radioactive DAGO. Computer analysis of the binding isotherm was used for quantitative analysis of the binding data and to resolve the Scatchard plots (Munson and Rodbard, 1980). This program utilizes non-linear regression to analyze the binding isotherm and assumes the simultaneous

FIGURE 3a. SPECIFIC BINDING OF RADIOLIGANDS (2 nM FINAL CONCENTRATION) TO GUINEA PIG SPINAL CORD MEMBRANES AS A FUNCTION OF INCUBATION TIME. Data are shown for [ $^3$ H]EKC ( $\Delta$ ), [ $^3$ H]DADLE ( $\square$ ), AND [ $^3$ H]DAGO ( $\circ$ ). N = 1.

FIGURE 3b. LOSS OF [ $^3$ H]EKC SPECIFIC BINDING IN GUINEA PIG BRAIN CORTEX MEMBRANES AS A FUNCTION OF TIME. Data shown for one of two similar experiments.

**A****B**





FIGURE 4. SPECIFIC BINDING OF RADIOLIGANDS (2nM FINAL CONCENTRATION) TO GUINEA PIG SPINAL CORD MEMBRANES AS A FUNCTION OF PROTEIN CONCENTRATION. Data points for each ligand were obtained using radioligand binding techniques described in Methods section. Data shown for [<sup>3</sup>H]EKC ( $\Delta$ ), [<sup>3</sup>H]DADLE ( $\square$ ), and [<sup>3</sup>H]DAGO ( $\circ$ ). N = 1.




FIGURE 5a. BINDING OF [ $^3$ H]DAGO TO GUINEA PIG SPINAL CORD MEMBRANES AT INCREASING RADIOLIGAND CONCENTRATIONS. Membranes were incubated with 1-50 nM concentrations of [ $^3$ H]DAGO as described in methods. Increasing quantities of [ $^3$ H]DAGO were added up to 10 nM. Higher concentrations achieved by adding non-radioactive DAGO. Total ( $\Delta$ ), non-specific ( $\square$ ), and specific(o). One of two representative experiments are shown.

FIGURE 5b. SCATCHARD PLOT OF SAME DATA. Solid line is computer fit of data from two similar curves (o) and ( $\bullet$ ).  $N = 2$ .

A



B



contribution of one or more independent binding sites. An F-statistic and runs-test is utilized to establish the best statistical fit for different models computed for the same data. The F-statistic compares the residual variances of each model and calculates a P-value (the probability that the improvement of fit of the more complex model is due to chance), a P-value of less than  $P < .05$  was required for us to choose the more complex model over the simpler model. The runs-test assumes that the order of the signs of the residuals (differences between the data point and the fitted curve) should be random. The level of significance of the pattern is calculated by the program. A  $P > .05$  for a runs-test for a single data set was judged as being an accurate computer model to fit the data. When multiple data sets were modeled together the runs-test was not utilized to evaluate "the goodness of fit" of the computer model for the data. Only a single site model could be fit to the [ $^3\text{H}$ ]DAGO saturation curve data (Fig. 5b). Computer analysis reveals a  $K_D$  of 6.0 nM and a  $B_{\text{MAX}}$  of 18 fmol/mg protein for this site. DAGO has been shown to be a highly  $\mu$  selective ligand (James and Goldstein, 1984; Hiller et al., 1984). Displacement of 5 nM [ $^3\text{H}$ ]DAGO with DAGO showed a  $K_I$  of 10 nM and a  $B_{\text{MAX}}$  of 14 fmol/mg protein (Fig. 6.). In addition, a Hill plot of the data showed a slope of 0.74 with  $R^2$  equal to 0.99 (inset Fig. 6.). Hill slope values of less than one may indicate complex binding to more than one receptor site. However, the previously reported  $\mu$  site receptor selectivity of DAGO would indicate that [ $^3\text{H}$ ]DAGO is only binding to  $\mu$  type receptor sites. Additional displacement studies of 5 nM [ $^3\text{H}$ ]DAGO binding were carried out to further characterize the receptor population labelled by [ $^3\text{H}$ ]DAGO (Fig. 7.). Nalbuphine HCl had a  $K_I$  of 11 nM and a  $B_{\text{MAX}}$  of 15 fmol/mg protein. Morphine sulfate had a  $K_I$  of 16 nM and a  $B_{\text{MAX}}$  of 13 fmol/mg protein. Therefore DAGO, morphine sulfate, and nalbuphine are three ligands with nearly equal affinity and  $B_{\text{MAX}}$  for  $\mu$  sites labelled by [ $^3\text{H}$ ]DAGO. U50488H, a putative  $\kappa$  selective ligand had a  $K_I$  of 2.0  $\mu\text{M}$  and a  $B_{\text{MAX}}$  of 14 fmol/mg protein, while DSTLE, a putative






FIGURE 6. SPECIFIC BINDING OF 5 nM [ $^3$ H]DAGO IN THE PRESENCE OF VARYING CONCENTRATIONS OF DAGO. Values are the means  $\pm$  standard error of the mean for three separate experiments performed in triplicate. Hill plot (insert) of the same data is shown. Y axis=  $\text{Log} (P/1-P)$  and  $P$  = % displacement of control binding.



FIGURE 7. SPECIFIC BINDING OF 5 nM [ $^3$ H]DAGO IN PRESENCE OF  
INCREASING CONCENTRATIONS OF UNLABELLED DISPLACERS.

A: Data are shown for DAGO ( $\blacktriangle$ ), Nalbuphine HCl ( $\bullet$ ), morphine sulfate ( $\blacksquare$ ). B: Data are shown for DAGO ( $\blacktriangle$ ), U50488H ( $\bullet$ ), and DSTLE ( $\blacksquare$ ). N = 2-3 for each curve shown.



$\delta$  selective ligand had a  $K_i$  of 161 nM and a  $B_{MAX}$  of 20 fmol/mg protein. Results of [ $^3H$ ]DAGO binding at  $\mu$  site are summarized in table 1. Thus [ $^3H$ ]DAGO binding is readily displaceable only by ligands having previously characterized high affinity at  $\mu$  type binding sites;  $\delta$  and  $\kappa$  selective ligands have relatively low potency. Thus [ $^3H$ ]DAGO binding appears to be almost exclusively to  $\mu$  type binding sites. However, Hill plots for displacing ligands have a low slope, and a shoulder may be apparent in some displacement curves. It is possible that DAGO has comparable affinity at two subtypes of the  $\mu$  receptor. This is discussed further in the discussion section.

An earlier report on opioid receptor binding in guinea pig lumbo-sacral spinal cord (Attali et al., 1982) claimed a lack of  $\mu$  binding as defined by the absence of specific binding of [ $^3H$ ]dihydromorphine or [ $^3H$ ]DADLE. These findings are not in agreement with our results in which saturation experiments with [ $^3H$ ]DAGO in both cervical-thoracic or lumbo-sacral guinea pig spinal cord showed binding to sites with  $\mu$  characteristics (Fig. 8a.). Scatchard plots for both tissue preparations were linear. Computer analysis produced a one site model with a  $K_D$  of 7 nM and a  $B_{MAX}$  of 18 fmol/mg protein for lumbo-sacral membranes and a single site model with a  $K_D$  of 9 nM and a  $B_{MAX}$  of 20 fmol/mg protein in cervical-thoracic membranes. These saturation experiments were not significantly different from one another at the  $P < 0.05$  level. Displacement of 5 nM [ $^3H$ ]DAGO binding in lumbo-sacral spinal cord membranes with morphine sulfate showed a  $K_i$  of 12 nM and a  $B_{MAX}$  of 21 fmol/mg protein while U50488H had an  $IC_{50} > 10 \mu M$  (Fig. 8b.). The site labelled by [ $^3H$ ]DAGO in lumbo-sacral spinal cord has similar  $K_D$  and  $B_{MAX}$  values as the site labelled by [ $^3H$ ]DAGO in whole spinal cord membrane saturation experiments. In addition the  $K_i$  for morphine in whole spinal cord and lumbo-sacral spinal cord are similar. Our results for binding studies in guinea pig lumbo-sacral spinal cord with [ $^3H$ ]DAGO indicate that the receptor population labelled has characteristics consistent with  $\mu$  opioid receptor site binding..

Table 1.

*Parameters for  $\mu$  site binding of [ $^3$ H]DAGO in guinea pig spinal cord measured by saturation and displacement studies.*

Parameters were derived by the LIGAND computer program for analysis of saturation or displacement data. For displacement experiments increasing concentrations of unlabelled ligand were used to compete against the binding of 5nM [ $^3$ H]DAGO. Saturation experiments were performed as described in methods.  $K_D$  and  $K_I$  values are expressed as nM, and  $B_{MAX}$  as fmol/mg protein. N = 2-3 for each value listed.

	$K_D$	$K_I$	$B_{MAX}$
<u>Experimental Condition</u>	<u>---</u>	<u>---</u>	<u>---</u>
[ $^3$ H] DAGO Scatchard	6.0	---	18
[ $^3$ H] DAGO Displaced With DAGO	---	10.0	14
[ $^3$ H] DAGO Displaced With Nalbuphine HCl	---	11	15
[ $^3$ H] DAGO Displaced With Morphine	---	15	13
[ $^3$ H] DAGO Displaced With DSTLE	---	161	20
[ $^3$ H] DAGO Displaced With U50488H	---	1900	14




FIGURE 8a. SPECIFIC BINDING OF [ $^3$ H]DAGO TO GUINEA PIG


LUMBO-SACRAL (o) AND CERVICAL-THORACIC (o) GUINEA PIG SPINAL CORD MEMBRANES. Membranes were incubated with 1-50 nM [ $^3$ H]DAGO. Increasing quantities of [ $^3$ H]DAGO were added up to 10 nM [ $^3$ H]DAGO, higher concentrations were achieved by adding non-radioactive DAGO. Data presented is one of two similar experiments. Solid line for each curve is the computer fitted parameter.

FIGURE 8b. SPECIFIC BINDING OF 5 nM [ $^3$ H] DAGO IN PRESENCE OF VARYING CONCENTRATIONS OF MORPHINE (●) AND U50488H (□) IN GUINEA PIG LUMBO-SACRAL SPINAL CORD. N = 1 for each value listed.

A



B



### Characterization of Specific Binding of [ $^3$ H]EKC

Specific binding was found to be saturable when membrane suspension was incubated with [ $^3$ H]EKC at concentrations of 0.1–50 nM (Fig 9a.). A curvilinear Scatchard plot was obtained from saturation curves for [ $^3$ H]EKC (Fig 9b.). A model of two independent binding sites fit the data better than a one-site model ( $F=18$   $P=.001$ ). The computer program could not fit a model with three sites. Assuming the existence of 2 independent binding sites, computer analysis reveals a high affinity site with a  $K_D$  of 1.0 nM and a  $B_{MAX}$  of 41 fmol/mg protein and a low affinity site with a  $K_D$  of 42 nM and a  $B_{MAX}$  of 158 fmol/mg protein. In order to examine the two components of [ $^3$ H]EKC binding, displacement studies with DAGO were carried out. From earlier results it can be seen that in our system DAGO was  $\mu$  site selective ligand. Displacement of 2.0 nM [ $^3$ H]EKC by increasing concentrations of DAGO revealed a high affinity site for DAGO displacement with a  $K_I$  of 5.5 nM, and a low affinity site that would have a  $K_I$  greater than 10  $\mu$ M (Fig 10a.). The high affinity displacement of 30 % of the 2 nM [ $^3$ H]EKC specific binding by DAGO is consistent with displacement of [ $^3$ H]EKC from  $\mu$  opioid receptor sites. Therefore a 1  $\mu$ M concentration of DAGO was selected as a concentration that could be utilized to block  $\mu$  receptor sites without blocking  $\kappa$  receptor sites in this system.

Displacement of 2.0 nM [ $^3$ H]EKC with U50488H revealed a high affinity site with a  $K_I$  of 2.3 nM, and a low affinity site with a  $K_I$  of 1.9  $\mu$ M (Fig. 10b) according to computer analysis. A slight shoulder can be seen at 1  $\mu$ M concentration U50488H in (Fig. 10b). A more pronounced shoulder could be seen in displacement studies of [ $^3$ H]EKC with U50488H in guinea pig cortex studies (Werling et al., 1984a). Based on this data a 1  $\mu$ M final concentration was selected to block  $\kappa$  binding and leave  $\mu$  receptors free. To be certain that [ $^3$ H]EKC was not binding to  $\delta$  receptors in our system, DSTLE a putative  $\delta$  selective ligand, was


FIGURE 9a. SPECIFIC BINDING OF [ $^3\text{H}$ ]EKC TO GUINEA PIG SPINAL CORD  
MEMBRANES AT INCREASING RADIOLIGAND CONCENTRATIONS.

Membranes were incubated with 0.1-50 nM concentration [ $^3\text{H}$ ]EKC as described in materials and methods. Increasing quantities of [ $^3\text{H}$ ]EKC were added up to 25 nM. Higher concentrations were achieved by adding non-radioactive EKC. Results of one of two similar experiments are shown.

FIGURE 9b. SCATCHARD PLOT OF SAME DATA. This plot was resolved into two components by a computerized non-linear regression program that assumes two independent binding sites. Dashed lines are computer fitted model of each independent binding site. Data from one of two representative experiments are shown.



A



B






FIGURE 10. SPECIFIC BINDING OF 2nM [<sup>3</sup>H]EKC IN PRESENCE OF VARYING CONCENTRATIONS OF DAGO AND U50488H. Each curve presented is a representative curve from two similar experiments. Data are shown for displacement with DAGO (A), and U50488H (B).

**A****B**

used to displace 2.0 nM [ $^3\text{H}$ ] EKC in both unblocked and 1  $\mu\text{M}$  DAGO blocked displacement studies (Fig. 11). DSTLE had a  $K_i$  of 45 nM when no DAGO was included. When 1  $\mu\text{M}$  DAGO was added to block [ $^3\text{H}$ ]EKC binding to  $\mu$  sites, DSTLE was unable to displace any specific binding even at 50  $\mu\text{M}$  final concentration. From these DSTLE displacement experiments one of two conclusions can be reached, either [ $^3\text{H}$ ]EKC has no measurable affinity at  $\delta$  receptors or 1  $\mu\text{M}$  DAGO block is a sufficient concentration to block [ $^3\text{H}$ ]EKC binding to  $\delta$  receptors if they are recognized by the labelled ligand. From these initial displacement studies it appeared possible to isolate opioid receptor subtypes in guinea pig spinal cord membranes. To assess if a 1  $\mu\text{M}$  DAGO block of [ $^3\text{H}$ ]EKC binding would be able to isolate a population of  $\kappa$  receptors, displacement of approximately 2 nM [ $^3\text{H}$ ]EKC with unlabelled EKC and U50488H was carried out with and without 1  $\mu\text{M}$  DAGO block. Displacement of [ $^3\text{H}$ ]EKC with EKC in an unblocked experiment had a  $\text{IC}_{50}$  of 63 nM; when the same experiment was repeated with 1  $\mu\text{M}$  DAGO block the  $\text{IC}_{50}$  was reduced to 1.2 nM with a  $K_i$  of 0.47 nM and a  $B_{\text{MAX}}$  of 30 fmol/mg protein (Fig. 12a.). In addition the Hill slope without a block was 0.56 and with a block the Hill slope increased to 0.73 (Inset Fig. 12a.). Displacement of [ $^3\text{H}$ ]EKC with U50488H in an unblocked experiment had an  $\text{IC}_{50}$  of 200 nM. When the same experiment was repeated with a 1  $\mu\text{M}$  DAGO block the  $\text{IC}_{50}$  was reduced to 31 nM with a  $K_i$  of 14 nM and a  $B_{\text{MAX}}$  of 29 fmol/mg protein (Fig. 12b.). Again the Hill Slope was increased from 0.36 without a block to 0.51 with a block (Inset Fig. 12b.). An attempt to study the  $\mu$  binding of [ $^3\text{H}$ ]EKC by displacement of [ $^3\text{H}$ ]EKC in the presence of 1  $\mu\text{M}$  U50488H block was not possible due to the very low residual specific binding. The small number of counts did not allow us to accurately construct a displacement curve.

Saturation analysis of 0.12–50 nM [ $^3\text{H}$ ]EKC binding was repeated under three conditions in parallel. These were: no blocking drugs, 1  $\mu\text{M}$  DAGO ( $\mu$  site block), and 1  $\mu\text{M}$  U50488H ( $\kappa$  site block). Without blocking concentrations of either U50488H or DAGO,








FIGURE 11. SPECIFIC BINDING OF 2 nM [ $^3$ H]EKC IN PRESENCE OF INCREASING CONCENTRATIONS DSTLE WITH AND WITHOUT 1  $\mu$ M DAGO BLOCK. Representative results from one of two experiments are presented. Data are shown for displacement by DSTLE without 1  $\mu$ M DAGO block(▲), and displacement by DSTLE with 1  $\mu$ M DAGO block (●).

FIGURE 12. SPECIFIC BINDING of 2 nM [ $^3$ H]EKC IN PRESENCE OF EKC WITH AND WITHOUT 1  $\mu$ M DAGO BLOCK (A), OR U50488H WITH OR WITHOUT 1  $\mu$ M DAGO BLOCK (B). Data are shown for displacement by EKC (A) without 1  $\mu$ M DAGO block ( $\blacktriangle$ ), and with 1  $\mu$ M DAGO block ( $\bullet$ ). Data are also shown for displacement with U50488H (B) without 1  $\mu$ M DAGO block ( $\blacktriangle$ ), and with 1  $\mu$ M DAGO block ( $\bullet$ ). Hill plot (inset) Y axis=  $\text{Log}(P/1-P)$  and  $P$ = % displacement of control binding. One of two representative experiments shown, except where indicated by \*,  $N = 1$ .


**A****B**

Scatchard transformation of the saturation curve for [ $^3\text{H}$ ]EKC showed a curvilinear plot (Fig. 13a.). Computer analysis preferred a model that assumed two independent binding sites over a one-site model ( $F=33$   $P=0.001$ ). Assuming the existence of two independent binding sites a high affinity site ( $\kappa$  site) with a  $K_D$  of 0.63 nM and a  $B_{\text{MAX}}$  of 42 fmol/mg protein and a low affinity site ( $\mu$  site) with a  $K_D$  of 44 nM and a  $B_{\text{MAX}}$  of 153 fmol/mg protein were identified. When 1  $\mu\text{M}$  DAGO block was used in the [ $^3\text{H}$ ]EKC saturation assay, Scatchard transformation of the data still produced a curvilinear plot (Fig. 13b.). When this data was subjected to computer analysis, a model assuming two independent binding sites fit the data better than a one-site model ( $F=93$   $P=.001$ ), a high affinity site with a  $K_D$  of 0.84 nM and a  $B_{\text{MAX}}$  of 31 fmol/mg protein, and a low affinity site with a  $K_D$  of 349 nM and a  $B_{\text{MAX}}$  of 665 fmol/mg protein were found. Finally, when a 1  $\mu\text{M}$  U50488H block was used in the [ $^3\text{H}$ ]EKC saturation assay, Scatchard transformation yielded a linear plot and computer modeling was only able to fit a one-site model with a  $K_D$  of 12 nM and a  $B_{\text{MAX}}$  of 90 fmol/mg protein (Fig. 13c.). The high  $B_{\text{MAX}}$  for the low affinity site in the saturation curves for [ $^3\text{H}$ ] EKC with and without a DAGO or U50488H block is too high to be consistent with the  $B_{\text{MAX}}$  measured for the  $\mu$  site by [ $^3\text{H}$ ]DAGO saturation or displacement curves. This high  $B_{\text{MAX}}$  is probably an artifact of saturable non-specific binding or the higher concentrations of [ $^3\text{H}$ ]EKC in the saturation experiments displacing the blocking ligand from  $\mu$  sites resulting in a false estimate of the density of the  $\mu$  site.

Additional displacement studies were performed to analyze ligand binding selectivity at an isolated  $\kappa$  site labelled with [ $^3\text{H}$ ]EKC in guinea pig spinal cord membranes. WIN 44,441-3, a putative selective  $\kappa$  antagonist and its positive isomer WIN 44,441-2, as well as two clinically useful analgesics, nalbuphine HCl and morphine sulfate, were used to displace 2 nM [ $^3\text{H}$ ]EKC. WIN 44,441-3 had a  $K_i$  of 0.69 nM and a  $B_{\text{MAX}}$  of 35 fmol/mg protein while



FIGURE 13. SPECIFIC BINDING OF [ $^3$ H]EKC TO GUINEA PIG SPINAL CORD MEMBRANES AT INCREASING RADIOLIGAND CONCENTRATIONS IN A PARALLEL EXPERIMENT. Membranes were incubated with 0.1-50 nM [ $^3$ H]EKC as described in Methods section. Increasing quantities of [ $^3$ H]EKC were added up to 25 nM and higher concentrations were achieved by adding non-radioactive EKC. Data presented is from one experiment without any blocking drugs (A), with 1  $\mu$ M DAGO block (B), and with 1  $\mu$ M U50488H block (C). N = 1 for each curve shown.



the positive isomer WIN 44,441-2 had a  $K_i$  of 1.9  $\mu$ M and a  $B_{MAX}$  of 48 fmol/mg protein. Morphine sulfate had a low affinity  $K_i$  of 5  $\mu$ M and a  $B_{MAX}$  of 39 fmol/mg protein at the isolated  $\kappa$  site labelled with [ $^3$ H]EKC. In the absence of a 1  $\mu$ M DAGO block, nalbuphine HCl displaced 2 nM [ $^3$ H]EKC with an  $IC_{50}$  of 100 nM and gave a Hill Slope of 0.84 (Fig. 14). In the presence of 1  $\mu$ M DAGO block the  $IC_{50}$  shifted to 400 nM and the Hill Slope was 0.91. The  $K_i$  for nalbuphine HCl at isolated  $\kappa$  receptors labelled with [ $^3$ H]EKC was 118 nM and had a  $B_{MAX}$  of 30 fmol/mg protein. The results of [ $^3$ H]EKC binding at the  $\kappa$  site are summarized in table 2.

#### Characterization of Specific Binding of [ $^3$ H]DADLE

Specific binding was found to be saturable when membrane suspension was incubated with increasing concentrations of [ $^3$ H]DADLE 0.3–30 nM (Fig. 15a.). Increasing concentrations of [ $^3$ H]DADLE were added up to 15 nM. Higher concentrations were achieved by adding non-radioactive DADLE. At higher concentrations of [ $^3$ H]DADLE non-specific binding was 70–80% of total binding. A linear Scatchard plot was obtained from transformation of saturation curves (Fig. 15b.). Computer analysis of [ $^3$ H]DADLE saturation curves preferred a one site model, with a  $K_D$  of 8.0 nM and a  $B_{MAX}$  of 28 fmol/mg protein. Previous work has shown that [ $^3$ H]DADLE discriminates poorly between  $\mu$  and  $\delta$  opioid receptors (Gillan and Kosterlitz, 1982; James and Goldstein, 1984), and labels  $\delta$  receptors with only a five fold preference over  $\mu$  receptors. Displacement of 5 nM [ $^3$ H]DADLE with DSTLE, a putative  $\delta$  selective ligand, was attempted in order to identify [ $^3$ H]DADLE binding to  $\mu$  and  $\delta$  subtypes (Fig. 16). DSTLE displaced specific [ $^3$ H]DADLE binding with an  $IC_{50}$  of 15 nM, and displacement of [ $^3$ H]DADLE was complete within two orders of magnitude. Hill plots of DSTLE displacement of [ $^3$ H]DADLE had a slope of 0.70 and a  $R^2$  of 0.93 (inset Fig. 16). DSTLE's




FIGURE 14. SPECIFIC BINDING OF 2 nM [ $^3$ H]EKC IN PRESENCE OF NALBUPHINE HCL WITH AND WITHOUT 1  $\mu$ M DAGO BLOCK. Data are shown for displacement without 1  $\mu$ M DAGO block ( $\blacktriangle$ ), and with 1  $\mu$ M DAGO block ( $\bullet$ ). Hill plot (inset) Y axis=  $\text{Log} (P/(1-P))$  and  $P$ = % displacement of control binding.  $N = 2-3$  for each curve shown.



Table 2



*Parameters for  $k$  site binding of [ $^3$ H]EKC in guinea pig spinal cord measured by saturation and displacement studies.*

Parameters were derived by the LIGAND computer program for analysis of saturation or displacement data. For displacement experiments increasing concentrations of unlabelled ligand were used to compete against the binding of 2 nM [ $^3$ H]EKC. Saturation experiments were performed as described in methods.  $K_D$  and  $K_I$  values are expressed as nM, and  $B_{MAX}$  as fmol/mg protein.  $N = 2-3$  for each value listed, except where indicated by \*, in which case  $N = 1$ .

	$K_D$	$K_I$	$B_{MAX}$
<u>Experimental Condition</u>	<u>---</u>	<u>---</u>	<u>---</u>
[ $^3$ H] EKC Scatchard	1.0	---	40
[ $^3$ H] EKC Scatchard Site 1, 1 $\mu$ M DAGO Block	0.84 *	---	31 *
[ $^3$ H] EKC Displaced With EKC, 1 $\mu$ M DAGO Block	---	0.5 *	30 *
[ $^3$ H] EKC Displaced With U50488H, 1 $\mu$ M DAGO Block	---	14.0	29
[ $^3$ H] EKC Displaced With Nalbuphine HCl, 1 $\mu$ M DAGO Block	---	118.0	30
[ $^3$ H] EKC Displaced With WIN 44,441-3, 1 $\mu$ M DAGO Block	---	0.70	35
[ $^3$ H] EKC Displaced With WIN 44,441-2, 1 $\mu$ M DAGO Block	---	1900.0	48

FIGURE 15a. SPECIFIC BINDING OF [ $^3\text{H}$ ]DADLE TO GUINEA PIG SPINAL CORD MEMBRANES AT INCREASING RADIOLIGAND CONCENTRATIONS. Membranes were incubated with 0.3–30 nM [ $^3\text{H}$ ]DADLE as described in Materials and Methods. Increasing concentrations of [ $^3\text{H}$ ]DADLE were added up to 15 nM. Higher concentrations were achieved by adding non-radioactive DADLE. Plot of saturation curve data show: total binding ( $\Delta$ ); non-specific binding ( $\square$ ); specific binding ( $\circ$ ). Data from one of two typical experiments shown

FIGURE 15b. SPECIFIC BINDING OF [ $^3\text{H}$ ]DADLE TO GUINEA PIG SPINAL CORD MEMBRANES AT INCREASING RADIOLIGAND CONCENTRATIONS IN ( $\bullet\bullet$ ) ABSENCE AND IN ( $\blacktriangle\blacktriangle$ ) PRESENCE OF 10 nM DAGO BLOCK. Data for ( $\bullet\bullet$ ) are experimental results described in Fig. 11b. Data for ( $\blacktriangle\blacktriangle$ ) are from 2 independent experiments where membranes were incubated with 0.5–25 nM [ $^3\text{H}$ ]DADLE. Solid lines are computer-generated fits for experiments with similar experimental conditions modelled together.






FIGURE 16. SPECIFIC BINDING OF 5 nM  $[^3\text{H}]\text{DADLE}$  IN PRESENCE OF VARYING CONCENTRATIONS OF DSTLE. (●) and (○) are data points from independent experiments. Hill plot of displacement experiments (inset) Y axis=  $\text{Log } (P/1-P)$  with  $P$ = % displacement of control binding.



inability to discriminate two binding sites for [ $^3\text{H}$ ]DADLE at  $\mu$  and  $\delta$ , resulted in our using DAGO, a  $\mu$  selective ligand for displacement of [ $^3\text{H}$ ]DADLE to achieve this goal. Displacement of 5 nM [ $^3\text{H}$ ]DADLE with DAGO showed a high affinity displacement with an  $\text{IC}_{50}$  of 3 nM and 80 % of control binding complete at 10 nM DAGO (Fig. 17). DAGO was unable to displace the remaining 20 % of control binding of [ $^3\text{H}$ ]DADLE even at 50  $\mu\text{M}$  concentrations of DAGO. Based on these experiments, a concentration of 10 nM DAGO was selected to block [ $^3\text{H}$ ] DADLE binding to  $\mu$  sites and allow binding studies of isolated  $\delta$  sites. Saturation analysis of 0.5-25 nM [ $^3\text{H}$ ]DADLE binding was repeated in the presence of 10 nM DAGO (Fig. 15b). Scatchard analysis of the data showed a linear plot. Computer analysis of this data fit a model that assumed the existence of a single type of opioid receptors, while a two site model was not compatible with the observed values. Assuming the existence of a single site, the computer fit a model with a  $K_D$  of 1.9 nM and a  $B_{\text{MAX}}$  of 6.0 fmol/mg protein. Blocking  $\mu$  sites with 10 nM DAGO resulted in an approximate four fold increase in [ $^3\text{H}$ ]DADLE's affinity for the remaining sites and a 80 % reduction in the number of receptor sites. Displacement studies of 5 nM [ $^3\text{H}$ ]DADLE binding in the presence of 10 nM DAGO block was not possible due to too few remaining specifically bound dpm (< 75 dpm). Increasing the concentration of [ $^3\text{H}$ ]DADLE to increase the amount of specific binding was not possible for two reasons. First the concentration of [ $^3\text{H}$ ]DADLE would be far above its  $K_D$  at  $\delta$  sites and second increasing the concentration of [ $^3\text{H}$ ]DADLE above 5 nM results in large increases of nonspecific binding. A solution to this problem may be to increase the amount of tissue (and assay volume) in order to increase specifically bound dpm. Displacement of 5 nM [ $^3\text{H}$ ]DADLE without DAGO block was carried out using nalbuphine HCl. Nalbuphine HCl had a  $\text{IC}_{50}$  of 31 nM and displacement of specific binding was complete at 10  $\mu\text{M}$  nalbuphine HCl. This  $\text{IC}_{50}$  is higher than its  $\text{IC}_{50}$  against [ $^3\text{H}$ ]DAGO binding to  $\mu$  sites, again suggesting that a component of [ $^3\text{H}$ ]DADLE binding has low affinity for nalbuphine. It is unlikely that nalbuphine has high affinity at the  $\delta$  site.




FIGURE 17. SPECIFIC BINDING OF 5 nM  $[^3\text{H}]\text{DADLE}$  IN PRESENCE OF VARYING CONCENTRATIONS OF DAGO. Results shown are from one of two similar experiments.

## Discussion

### Heterogeneity of Spinal Opioid Receptors

It is clear from these data that the opiate receptors in the spinal cord are heterogeneous like those in brain (Kosterlitz et al., 1981; James and Goldstein, 1984; Werling et al., 1984c). It is also clear that guinea pig spinal cord has a lower density of receptors than guinea pig cortex Table 3. The  $K_D$ 's of [ $^3H$ ]DAGO at  $\mu$  sites, [ $^3H$ ]DADLE at  $\delta$  sites and [ $^3H$ ]EKC at  $\kappa$  sites are similar for all neural tissues studied in this laboratory under our conditions. The relative proportions of  $\mu$ ,  $\delta$  and  $\kappa$  receptors are similar for guinea pig cortex and spinal cord. In rat whole brain there are fewer  $\kappa$  receptors and more  $\mu$  and  $\delta$  receptors. Thus, species differences influence the relative content of  $\mu$ ,  $\delta$  and  $\kappa$  receptors in a given tissue but appear to have a minimal effect on the affinity of a radioligand at an isolated opioid receptor type. In our work with whole guinea pig spinal cord we noted a total opioid receptor density of 50 fmol/mg protein. The relative content of  $\mu$ ,  $\delta$  and  $\kappa$  receptors in guinea pig spinal cord are in good agreement with the relative content of opioid receptor types in postmortem whole human spinal cord and guinea pig lumbo-sacral cord described by Czlonkowski and co-workers (1983). However the density of opioid receptor types in whole human spinal cord minus cervical segments (Czlonkowski et al., 1983) was 22 fmol/mg protein. The addition of sodium to our assay system would be anticipated to produce a reduction in the density of only  $\delta$  type opioid receptors (Werling et al., 1984b), which are only 10 % of the total opioid receptors in guinea pig spinal cord. Therefore the addition of sodium to our assay system would only be expected to produce a small decrease in the total density of opioid receptors in whole spinal cord tissue. It is possible that the 1.5 - 5.5 hour delay from time of death to removal of human postmortem spinal cord tissue resulted in a slow degradation of tissue, and in a proportional decrease of all opioid receptor types. Rat whole spinal cord had a three fold greater density of opiate receptors (Mack et al., 1984) than we found in these studies in whole guinea pig spinal cord. The relative content of  $\mu$ ,  $\delta$  and  $\kappa$  opioid

**Table 3.***Parameters for binding of radioligands in guinea pig and rat neural tissue*

Parameters were derived by using the LIGAND computer program to analyze saturation data. [ $^3\text{H}$ ]DAGO was used to characterize  $\mu$  binding, [ $^3\text{H}$ ]DADLE in the presence of 10nM DAGO for  $\delta$  binding, and [ $^3\text{H}$ ]EKC in the presence of 1  $\mu\text{M}$  DAGO for K binding.  $K_D$  values are expressed in nM, and  $B_{\text{max}}$  values as fmol/mg protein. Percentages in parentheses following  $B_{\text{max}}$  values are proportions of total receptor number represented by that receptor type. For guinea pig cortex,  $n = 2-6$  for each  $K_D$  and  $B_{\text{max}}$  listed; for other preparations  $n = 2-3$ .

	$\mu$		$\delta$		K	
	$K_D$	$B_{\text{max}}$	$K_D$	$B_{\text{max}}$	$K_D$	$B_{\text{max}}$
<b>Guinea Pig Cortex *</b>	6.7	36 (23%)	2.5	18 (12%)	1.4	10 (68%)
<b>Guinea Pig Spinal Cord</b>	6.0	18 (30%)	1.9	6.1 (10%)	1.4	35 (59%)
<b>Guinea Pig Striatum *</b>	7.2	32 (20%)	4.7	41 (26%)	1.0	87 (54%)
<b>Rat Whole Brain *</b>	7.2	70 (47%)	3.5	51 (34%)	1.6	29 (19%)

\* Work From:

Werling, L. L., Zarr, G., and Cox, B.M. : Opioid binding characteristics of rat and guinea pig brain membranes in the presence of physiological cations at 37°C. (Manuscript in preparation)



receptors in rat spinal cord reported by Mack and co-workers is in good agreement with the relative proportion of opioid receptors in rat brain reported by Werling and co-workers (1984c). It is important to remember that the content of  $\kappa$  receptors in rat spinal cord is 13% while the relative proportions of  $\delta$  receptors is 33% of total opioid receptors (Mack et al., 1984). Previous intrathecal opiate analgesia studies in rats using drugs thought to have  $\kappa$  agonist properties (Schmauss et al., 1984) may have underestimated the potency of these compounds due to the low number of  $\kappa$  receptors in rat spinal cord for  $\kappa$  agonists to bind to and produce a pharmacologic effect. Use of an animal model with a relative concentration of opioid receptors closer to that of man may yield potency estimates for  $\kappa$  agonists that would have greater clinical relevance.

#### Lumbo-sacral Spinal Cord Opioid Receptors

Our work in guinea pig lumbo-sacral spinal cord has demonstrated the existence of specific binding of [ $^3$ H]DAGO, a  $\mu$  opioid receptor agonist. The binding parameters for [ $^3$ H]DAGO in lumbo-sacral spinal cord are similar to those seen in whole guinea pig lumbo-sacral spinal cord. Displacement of [ $^3$ H]DAGO in lumbo-sacral spinal cord with morphine and U50488H also indicate that the binding of [ $^3$ H]DAGO in guinea pig lumbo-sacral spinal cord is to a site with  $\mu$  opioid receptor characteristics. The demonstration of  $\mu$  binding in guinea pig lumbo-sacral spinal cord is in agreement with work by Czlonkowski and co-workers who found  $\mu$  binding in guinea pig, rat and human lumbo-sacral spinal cord. These findings are not in agreement with previous reports of absence of  $\mu$  binding in rat and guinea pig lumbo-sacral spinal cord (Attali et al., 1982; Gouarderes et al., 1982). The absence of specific binding for [ $^3$ H]DHM or [ $^3$ H]DADLE in guinea pig lumbo-sacral spinal cord lead Attali and co-workers to assume the absence of  $\mu$  or  $\delta$  opioid receptor binding in this tissue. The reasons for this group's inability to identify specific binding for [ $^3$ H]DHM or [ $^3$ H]DADLE remains uncertain, but may be a result of a high level of non-specific relative to specific binding in this tissue. Attali and co-workers



proposed the existence of two receptor sites that could be isolated by the differential effects of a 5  $\mu\text{M}$  DADLE block on [ $^3\text{H}$ ]EKC binding. These two sites were termed DADLE sensitive site ( $\text{DAL}_s$ ) which was a portion of the [ $^3\text{H}$ ]EKC binding that was lost when a 5  $\mu\text{M}$  DADLE block was utilized. The use of a 5  $\mu\text{M}$  DADLE block resulted in the loss of [ $^3\text{H}$ ]etorphine binding as well. The DADLE insensitive site ( $\text{DAL}_i$ ) was defined by the binding of [ $^3\text{H}$ ]EKC that remained when a 5  $\mu\text{M}$  DADLE block was used. The  $\text{DAL}_i$  site had a  $K_D$  of 0.36 nM and a  $B_{\text{MAX}}$  of 30 fmol/mg protein. The  $\text{DAL}_i$  site was proposed to have characteristics similar to a k site identified in guinea pig brain by Kosterlitz and co-workers (1981). Our work in whole guinea pig spinal cord revealed a single k site with a  $K_D$  of 0.84 nM and a  $B_{\text{MAX}}$  of 31 fmol/mg protein. We believe that this isolated k site is the same site that Attali and co-workers (1982) identified in guinea pig lumbo-sacral spinal cord because the  $K_D$ 's and the  $B_{\text{MAX}}$ 's are quite similar. The 2.3 fold reduction in the affinity of [ $^3\text{H}$ ]EKC at this site is due to the addition of salts to our assay system. Assuming that our results showing that  $\mu$  opioid receptor binding is present in lumbo-sacral spinal cord is correct, a portion or all of the  $\text{DAL}_s$  site would be due to DADLE blocking [ $^3\text{H}$ ]EKC to  $\mu$  binding sites and not DADLE blocking [ $^3\text{H}$ ]EKC binding to benzomorphan sites as proposed (Attali et al., 1982). Scatchard transformation of [ $^3\text{H}$ ]EKC saturation curves in the presence of 5  $\mu\text{M}$  DADLE block remained curvilinear with a low affinity site that had a  $K_D$  of 5.6 nM and a  $B_{\text{MAX}}$  of 108 fmol/mg protein. Attali and co-workers did not address the issue of what receptor site could be associated with this low affinity site. In our Scatchard transformations and computer modelling of [ $^3\text{H}$ ]EKC saturation curves we noted a low affinity site for [ $^3\text{H}$ ]EKC binding in whole guinea pig spinal cord both in the presence and the absence of 1  $\mu\text{M}$  DAGO block. In our unblocked [ $^3\text{H}$ ]EKC saturation curves the density of these sites is too high to be only  $\mu$  receptor sites. The possibility exists that a portion of this low affinity site is a

benzomorphan site. However, when a 1  $\mu$ M DAGO block is used in [ $^3$ H]EKC saturation curves, the density of the low affinity site increases 5 fold. This type of finding is most consistent with high concentrations of [ $^3$ H]EKC displacing the DAGO block from  $\mu$  sites and the labelling of a component of saturable low affinity non-specific binding resulting in the artifactual appearance of an additional binding site. In view of our findings and those of Czlonkowski and co-workers (1983), interpretation of binding experiments in lumbo-sacral spinal cord under the assumption of absence of  $\mu$  or  $\delta$  binding may lead to inaccurate conclusions.

#### Mu Receptor Subtypes

The existence of  $\mu_1$  and  $\mu_2$  opioid receptor subtypes (Pasternak et al., 1980) in whole or lumbo-sacral guinea pig spinal cord has not been established at this time. The broad displacement of [ $^3$ H]DAGO by DAGO and DSTLE in whole spinal cord (Fig. 7b) and morphine in lumbo-sacral spinal cord (Fig. 8b) may be an indication that [ $^3$ H]DAGO is not binding to a homogeneous population of opioid receptors in this tissue. In addition, Scatchard transformations of [ $^3$ H]DAGO saturation curves in lumbo-sacral and cervical-thoracic spinal cord have a slightly curvilinear appearance. However, computer analysis is unable to fit this data to a two site model. Additional [ $^3$ H]DAGO saturation curves with more low concentration points as well as additional displacement studies with DSTLE and DAGO may be able to establish firm evidence for  $\mu$  subtypes in guinea pig spinal cord. Should further studies establish evidence for  $\mu$  subtypes in this tissue, naloxazone or naloxonazine blocking could be added to these studies. Past work with naloxazone (Pasternak et al., 1980) and naloxonazine (Houghton et al., 1984) has shown that these long lasting opioid antagonists have a preference for  $\mu_1$  sites. Addition of naloxazone or naloxonazine to saturation or displacement assays would be expected to produce a loss of the very high affinity, low capacity binding that would be associated with  $\mu_1$

binding and have no effect on the lower affinity  $\mu_2$  binding site. The work of Pasternak and co-workers (1980) showed that in mice,  $\mu_1$  sites seemed to have a selective role in producing morphine analgesia and that loss of these sites by *in vivo* naloxazone injections, resulted in loss of analgesia from morphine administration. Should further research establish firm evidence of  $\mu_1$  opioid receptor subtypes, and a selective ligand for these sites be developed, systemic or intrathecal opiate analgesia without significant respiratory depression might be possible.

#### Delta Opioid Receptors

These data clearly establish the existence of  $\delta$  receptors in guinea pig spinal cord. The low density of  $\delta$  receptors in this tissue and the high non-specific binding of [ $^3$ H]DADLE in this system present a technical difficulty when trying to characterize various ligand affinities at isolated  $\delta$  sites labelled with [ $^3$ H]DADLE in the presence of a 10 nM DAGO block. The amount of specific binding that remains under these conditions is less than 100 dpm. This amount of specific binding is not sufficient to construct accurate displacement curves under our assay conditions. Increasing the concentration of [ $^3$ H]DADLE to increase the bound dpm is not possible because the concentration of radioligand needs to be near the  $K_D$  of  $\delta$  sites. The introduction of a highly selective  $\delta$  radioligand with lower non-specific binding than [ $^3$ H]DADLE may allow for further radioligand binding characterization of  $\delta$  sites in this system.

#### Nalbuphine HCl Affinities at Isolated $\kappa$ and $\mu$ Opioid Receptor Sites

The data for nalbuphine HCl show a ten fold selectivity for  $\mu$  binding in guinea pig whole spinal cord. These *in vitro* binding results do not indicate the agonistic or antagonistic activity of nalbuphine HCl on isolated opioid receptor sites. Further displacement studies with nalbuphine HCl at isolated  $\mu$  and  $\kappa$  receptor sites in the presence and absence of manganese may



provide biochemical evidence of nalbuphine's agonistic or antagonistic activity at isolated opioid receptor sites. It has been shown that manganese in the presence of sodium increases the binding of agonist opiates while having little effect on the binding of antagonists (Pasternak et al., 1975). The results of co-administration of nalbuphine HCl and morphine intrathecally in rats (Schamauss et al., 1983) would suggest that nalbuphine HCl is an agonist at  $\kappa$  sites and an antagonist at  $\mu$  sites. Bioassay techniques in electrically stimulated GPI that has been pretreated by site directed alkalation to produce an enriched population of desired opioid receptors (James et al., 1982) would provide information as to nalbuphine's agonistic and antagonistic properties at isolated receptor sites.

#### Comparison of *In Vitro* $K_D$ and $K_I$ Values With *In Vivo* $EC_{50}$ Estimates

There is good agreement between published  $EC_{50}$  values for *in vivo* opiate and opioid analgesia and estimates of binding affinities derived for isolated opioid receptor sites from *in vitro* radioligand binding studies presented in these data. Yaksh (1981) has published intrathecal  $EC_{50}$  values for a wide variety of opiate and opioid drugs. Morphine has an  $EC_{50}$  of 12.7 nM, while in our morphine displacement assays of  $\mu$  sites labelled with [ $^3H$ ]DAGO, morphine had a  $K_I$  of 15 nM. DADLE had an  $EC_{50}$  of 11.4 nM. In our unblocked [ $^3H$ ]DADLE saturation curves where [ $^3H$ ]DADLE is binding to both  $\mu$  and  $\delta$  sites a  $K_D$  of 8 nM was noted. When comparing  $EC_{50}$  and  $K_D$  values for DADLE, it is reasonable to use  $K_D$  values derived from unblocked saturation curves, since in the *in vivo* intrathecal opioid model DADLE is most likely producing its analgesia via both  $\mu$  and  $\delta$  receptors (Yaksh, 1984). The  $EC_{50}$  for EKC in rat spinal cord was 52.9 nM. This is a value that is close to our measured  $K_D$  of 40 nM for [ $^3H$ ]EKC at  $\mu$  sites in guinea pig spinal cord. The analgesic activity of EKC in rat spinal cord is most

likely due to binding to  $\mu$  receptors since the density of  $\kappa$  receptors is low in rat spinal cord (Mack et al., 1984).

These comparisons suggest a remarkable similarity between estimates of potency and affinity at the receptors apparently mediating the spinal analgesia. However, the similarity should be treated with caution. The opioid potency estimates are based on assumptions regarding the volume of distribution of the intrathecally administered opioid which may not be correct. Secondly, in other opioid systems which have been studied in more detail, there is evidence for the existence of "spare" receptors. If there were spare receptors on neurons mediating opioid analgesia in spinal cord,  $EC_{50}$  values would be expected to be lower than estimates of receptor affinity. It remains to be determined if  $\kappa$ -agonists have a higher analgesic potency in species with a higher density of  $\kappa$  type receptors. It would also be of interest to compare potencies of  $\kappa$  agonists in the relief of chemically mediated pain in species with relatively high and low concentrations of  $\kappa$  receptors, in view of the suggestion by Schmauss and co-workers (1983) that this kind of painful stimulus is particularly susceptible to  $\kappa$  agonist induced analgesia.



## Conclusions

These data clearly establish the heterogeneity of opioid receptors in guinea pig spinal cord under more physiologic assay conditions than have been used in past studies. The relative proportion of opioid receptor types in the spinal cord is in close agreement with the relative proportion of receptor types in guinea pig cortex. In addition, these data clearly show that  $\mu$  binding exists in guinea pig lumbo-sacral spinal cord. These data also show the binding affinities of two clinically useful spinal analgesics, nalbuphine HCl and morphine sulfate. It is apparent from these data that morphine, a  $\mu$  selective ligand, and DSTLE, a  $\delta$  selective ligand, have very low affinity at isolated  $\kappa$  sites. Morphine sulfate in displacement studies of 2 nM [ $^3$ H]EKC, in presence of 1  $\mu$ M DAGO block, had an  $IC_{50}$  greater than 5  $\mu$ M. While DSTLE had no measurable affinity at isolated  $\kappa$  sites labelled by 2 nM [ $^3$ H]EKC in the presence of 1  $\mu$ M DAGO block. Displacement of [ $^3$ H]DAGO binding with morphine, DSTLE, and DAGO all show possible evidence of binding to  $\mu_1$  and to  $\mu_2$  sites. In this system DAGO remains a  $\mu$  site selective ligand but may be able to discriminate subtypes of  $\mu$  receptors. The affinities of morphine and EKC at  $\mu$  sites, and DADLE at  $\mu$  and  $\delta$  sites, correspond closely with their reported  $EC_{50}$  in inducing spinal analgesia in the rat.

Radioligand receptor binding studies in tissue homogenates can give quantitative information about the density and relative proportions of opioid receptor types and binding affinities of these receptors for various ligands. However, radioligand receptor binding studies can not provide information about the anatomic localization of opioid receptors. Future studies in selected levels of guinea pig spinal cord, utilizing opiate and opioid site selective radioligand binding studies in slices of spinal cord tissue and autoradiographic techniques combined with computer analysis of autoradiograms, could provide quantitative as well as qualitative information about opioid receptors in this tissue. In addition these types of studies could provide information as to the location of opioid receptor types in spinal cord and the potential functions

of each receptor type in the regulation of different aspects of spinal cord function. Several lines of evidence suggest that spinal cord opioids have functions in systems unrelated to processing of pain sensation. Comparison of receptor selective opioid potencies in some of these systems with estimates of their affinities at isolated opioid binding sites under physiological conditions may assist in the identification of the receptor types mediating these affects.

## Bibliography

- Akil, H., Hewlett, W.A., Borchas, J.D. and Li, C.H. Binding of [ $^3\text{H}$ ]B-endorphin to rat brain membranes: characterization of opiate receptors and interaction with ACTH. *Eur. J. Pharmacol.* 64: 1 - 8, 1980.
- Attali, B., Gouarderes, C., Mazarquil, H., Rudigier, Y. and Cros, J. Evidence for multiple "kappa" binding sites by the use of opioid peptides in the guinea pig lumbo-sacral spinal cord. *Neuropeptides* 3: 53 - 64, 1982.
- Barchfeld, C.C. and Medzihradsky, F. Receptor-mediated stimulation of brain GTPase by opiates in normal and dependent rats. *Biochemical and Biophysical Res. Comm.* 121: 641 - 648, 1984.
- Basbaum, A.I. and Fields, H.L. Endogenous pain control mechanisms: review and hypothesis. *Ann. Neurology* 4: 451 - 462, 1978.
- Behar, M., Olshwang, D., Magora, F. and Davidson, J.T. Epidural morphine in treatment of pain. *Lancet* 527 - 528, 1979.
- Blume, A.J., Lichshtein, D. and Boone, A. Coupling of opiate receptors to adenylate cyclase: requirement for  $\text{Na}^+$  and GTP. *Proc. Natl. Acad. Sci. USA* 76: 5626 - 5630, 1979.
- Botticelli, L.J., Cox, B.M. and Goldstein, A. Immunoreactive dynorphin in mammalian spinal cord and dorsal root ganglia. *Proc. Nat. Acad. Sci. USA* 78: 7783 - 7786, 1981.
- Bromage, P.R., Comporesi, E. and Chestnut, D. Epidural narcotics for post operative analgesia. *Anesth. Analg. Curr. Res.* 59: 473 - 480, 1980.
- Chang, K.J., Hazum, E. and Cuatrecasas, P. Novel opiate binding sites selective for benzomorphan drugs. *Proc. Natl. Acad. Sci. USA* 78: 4141 - 4145, 1981.
- Chang, K.-J., Blanchard, S.G. and Cuatrecasas, P. Unmasking of magnesium-dependent high affinity binding sites for [ $\text{D-Ala}^2$ - $\text{D-Leu}^5$ ] enkephalin after pretreatment of brain membranes with guanine nucleotides. *Proc. Nat. Acad. Sci. USA* 80: 940 - 944, 1983.
- Chang, Y.-C. and Prusoff, W.H. *Biochem. Pharmacol.* 22: 3099 - 3108, 1973.

- Childers, S.R. and Snyder, S.H. Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors. *Life Sci.* 23: 759 - 762, 1978.
- Childers, S.R. and Snyder, S.H. Differential regulation by guanine nucleotides of opiate agonist and antagonist receptor interactions. *J. Neurochem.* 34: 583 - 593, 1980.
- Collier, H.O.J. and Roy, A.C. Morphine-like drugs inhibit the stimulation by E prostaglandins of cyclic AMP formation by rat brain homogenate. *Nature* 248: 24 - 27, 1974.
- Cooper, D.M.F., Londos, C., Gill, D.L. and Rodbell, M. Opiate receptor-mediated inhibition of adenylate cyclase in rat striatal plasma membranes. *J. Neurochem.* 38: 1164 - 1167, 1982.
- Cousins, M.J., Mather, L.E., Glynn, C.J., Wilson, P.R. and Graham, J.R. Selective spinal analgesia. *Lancet* 1141 - 1142, 1979.
- Cox, B.M. and Chavkin, C. Comparison of dynorphin-selective kappa receptors in mouse vas deferens and guinea pig ileum. *Mol. Pharmacol.* 23: 36 - 43, 1983.
- Cox, B.M., Goldstein, A. and Li, C.H. Opioid activity of a peptide B-lipotropin-(61 - 91), derived from B-lipotropin. *Proc. Nat. Acad. Sci. USA* 73: 1821 - 1823, 1976.
- Cox, B.M., Leslie, F.M. and Chavkin, C. Characteristics of peptide and alkylid opiate binding sites in brain and peripheral tissues. *Neural Peptides and Neuronal Communication*: 353 - 362, 1980.
- Cox, B.M. and Weinstock, M. The effect of analgesic drugs on release of acetylcholine from electrically stimulated guinea-pig ileum. *Brit. J. Pharmacol. Chemother.* 27: 81 - 92, 1966.
- Cox, B.M., Leslie, F.M. and Dunlap, C.E. III The use of ascorbate as a probe of opioid receptor structure: evidence for two independent mechanisms of receptor destruction by ascorbate. *Journal of Receptor Research* 1(2): 329 - 354, 1980.
- Cox, B.M., Opheim, K.E., Teschemacher, H. and Goldstein, A. A peptide like substance from pituitary that acts like morphine. 2. Purification and properties. *Life Sci.* 16: 1777 - 1782, 1975.



- Cox, B.M., Werling, L.L., Zarr, G. Regulation of agonist binding to opiate receptor types by sodium and GTP: relevance to receptor function. NIDA Research Monograph (in press), 1984.
- Czlonkowski, A., Costa, T., Przewlocki, R., Pasí, A. and Herz, A. Opiate receptor binding sites in human spinal cord. *Brain Res.* 267: 392 - 396, 1983
- Dunlap, C.E. III, Leslie, F.M., Rado, M. and Cox, B.M. Ascorbate destruction of opiate stereospecific binding in guinea pig brain homogenate. *Molecular Pharmacology* 16: 105 - 119, 1979.
- Elde, R., Hokfelt, T., Johnson, O. and Terenius, L. Immunohistochemical studies using antibodies to leucine-enkephalin: initial observations on the nervous system of the rat. *Neuroscience* 1: 349 - 351, 1976.
- Ferrana, P. and Li, C.H. B-endorphin: characterization of binding sites in rabbit spinal cord. *Proc. Nat. Acad. Sci. USA* 77: 5746 - 5748, 1980.
- Fields, H.L., Emson, P.C., Leigh, B.K., Gilbert, R.F.T. and Iverson, L.L. Multiple opiate receptor sites on primary afferent fibers. *Nature (London)* 284: 351 - 353, 1980.
- with primary sensory afferents. *Brain Res.* 248: 223 - 236, 1982.
- Frey, E.A. and Kebabian, J.W. A  $\mu$ -opiate receptor in 7315c tumor tissue mediates inhibition of immunoreactive prolactin release and adenylate cyclase activity. *Endocrinology* 115: (In Print), 1984.
- Gillan, M.G.C. and Kosterlitz, H.W. Spectrum of the  $\mu$ -,  $\delta$ - and K-binding sites in homogenates of rat brain. *Br. J. Pharmacol.* 77: 461 - 469, 1982.
- Gilbert, P.E. and Martin, W.R. The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent, and cyclazocine dependent chronic spinal dog. *J. Pharmacol. Exp. Ther.* 198: 66 - 82, 1976.
- Gobel, S., Falls, W. M., Bennett, G.T., Abdelmoumene, M., Hyashi, H. and Humphery, E. An EM analysis of the synaptic connections of horseradish peroxidase-filled stalked cells and islet cells in the substantia gelatinosa of adult cat spinal cord. *J. of Comparative Neurology* 194:

781 - 807, 1980.

Gobel, S. An electron microscopic analysis of the trans-synaptic effects of peripheral nerve injury subsequent to tooth pulp extirpations on neurons in laminae I and II of medullary dorsal horn. *J. Neuroscience* 4: 2281 - 2290, 1984.

Goldstein, A. and Lowney, L.I. A novel opioid from beef brain. *INRC Abstracts* 50, 1984.

Goldstein, A., Lowney, L.I. and Pal, B.K. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. *Proc. Nat. Acad. Sci. USA* 68: 1742 - 1747, 1971.

Goldstein, A., Tachibana, S., Lowney, L.I., Hunkapiller, M. and Hood, L. Dynorphin -(1 - 13), an extraordinary potent opioid peptide. *Proc. Nat. Acad. Sci. USA* 76: 6666 - 6670, 1979.

Goodman, R.R., Snyder, S.H., Kuhar, M.J. and Young, W.S. Differentiation of delta and mu opiate receptor localizations by light microscopic autoradiography. *Proc. Nat. Acad. Sci. USA* 77: 6239 - 6243, 1980.

Gouarderes, C., Audigier, Y. and Cros, J. Benzomorphan binding sites in rat lumbo-sacral spinal cord. *European J. of Pharmacol.* 78: 483 - 486, 1982.

Hagan, R.M. and Hughes, I.E. Opioid receptor subtypes involved in control of transmitter release in cortex of the brain of rat. *Neuropharm.* 23: 491 - 495, 1984.

Henderson, G., Hughes, J. and Kosterlitz, H.W. A new example of morphine-sensitive neuro-effector junction: adrenergic transmission in mouse vas deferens. *Brit. J. Pharmacol.* 46: 764 - 766, 1972.

Hiller, J.M., Angle, L.M. and Simon, E.J. Characterization of the selective inhibition of the delta subclass of opioid binding sites by alcohols. *Mol. Pharmacol.* 25: 249 - 255, 1984.

Hiller, J.M., Pearson, J. and Simon, E.J. Distribution of stereospecific binding of the potent narcotic analgesic etorphine in human brain: predominance in the limbic system. *Res. Commun. Chem. Pathol. Pharm.* 6: 1052 - 1062, 1973.

Houghten, R.A., Johnson, N. and Pasternak, G.W. [ $^3$ H]B-endorphin binding in rat brain. *Soc. for Neurosci.* 4: 2460 - 2465, 1984.

- Hunt, S.P., Kelly, J.S. and Emson, P.C. The electron microscopic localization of methionine enkephalin within superficial layers (I and II) of spinal cord. *Neuroscience* 5: 1871 - 1890, 1980.
- Hughes, J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. *Brain Res.* 88: 295 - 308, 1975a.
- Hughes, J., Smith, T.W., Kosterlitz, H.W., Fothergill, L.A., Morgan, B.A. and Morris, H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. *Nature (London)* 258: 577 - 579, 1975b.
- James, I.F., Chavkin, C. and Goldstein, A. Preparation of brain membranes containing a single site of opiate receptor highly selective for dynorphin. *Proc. Natl. Acad. Sci. USA* 79: 7570 - 7574, 1982.
- James, I.F. and Goldstein, A. Site-directed alkylation of multiple opiate receptors: I. Binding selectivity. *Mol. Pharmacol.* 25: 337 - 342, 1984.
- Jessel, T.M., Iversen, L.L. and Cuello, A.C. Capsaicin-induced depletion of substance P from primary sensory neurons. *Brain Res.* 152: 183 - 188, 1978.
- Kakadani, H., Furutani, Y., Takahashi, H., Noda, M., Morimoto, Y., Hirose, T., Asai, M., Inayama, S., Nakanishi, S. and Numa, S. *Nature* 298: 245 - 249, 1982.
- Kandel, E.R. and Schwarz, J.H. Molecular biology of learning: modulation of transmitter release. *Science* 218: 433 - 443, 1982.
- Kelly, P.D., Lane, A.C., Rance, M.J. and Traynor, J.R. Opiate receptors in rat spinal cord. *Brit. J. Pharmacol.* 70: 153P - 154P, 1980.
- Koski, G. and Klee, W.A. Opiates inhibit adenylate cyclase by stimulating GTP hydrolysis. *Proc. Nat. Acad. Sci. USA* 78: 4185 - 4189, 1981.
- Kosterlitz, H.W., Paterson, S. J. and Robinson, L.E. Characterization of the kappa subtype of opiate receptor in the guinea pig brain. *Br. J. Pharmacol.* 73: 939 - 949, 1981.
- Lamotte, C. Pert, C.B. and Synder, S.H. Opiate receptor binding in primate spinal cord distribution and changes after dorsal root section. *Brain Res.* 112: 407 - 412, 1976.



- Law, P.Y., Loh, H.H. and Li, C.H. Properties and localization of B-endorphin receptor in rat brain. *Proc. Nat. Acad. Sci. USA* 76: 5455 - 5459, 1979.
- Law, P.Y., Wu, J., Koehler, J.E. and Loh, H.H. Demonstration and characterization of opiate inhibition of the striatal adenylyate cyclase. *J. Neurochem.* 36: 1834 - 1846, 1981.
- Lembeck, F., Donnerer, J. and Colpaert, F.C. Increase of substance P in primary afferent nerves during chronic pain. *Neuropeptides* 1: 175 - 180, 1981.
- Leslie, F.M., Chavkin, C. and Cox, B.M. Opioid binding properties of brain and peripheral tissues: Evidence for heterogeneity in opioid binding sites. *J. Pharmacol. Expt. Ther.* 214: 395 - 402, 1980.
- Lewis, M.E., Khachaturian, H. and Watson, S.J. Comparative distribution of opiate receptors and three opioid peptide neuronal systems in rhesus monkey central nervous system. *Life Sci.* 33: Supl, 239 - 242, 1983.
- Li, C.H., Barnafi, L., Chretien, M. and Chung, D. Isolation and amino acid sequence of  $\beta$ -LPH from sheep pituitary glands. *Nature (London)* 208: 1093 - 1094, 1965.
- Lord, J.A.H., Waterfield, A.A., Hughes, J., and Kosterlitz, H.W. Endogenous opioid peptides: multiple agonists and receptors. *Nature* 267: 495 - 499, 1977.
- Lowney, L.I., Gentlemon, S.B. and Goldstein, A. A pituitary endorphin with novel properties. *Life Sci.* 24: 2377 - 2384, 1979.
- Mack, K.J., Killian, A. and Weyhenmeyer, J.A. Comparison of Mu, Delta, and Kappa opiate binding sites in rat brain and spinal cord. *Life Sci.* 34: 281 - 285, 1984.
- Magora, T., Olshwang, D., Eimerl, D., Shorr, J., Kalzenelson, R., Cotev, S. and Davidson, J.T. Observations on extradural morphine analgesia in various pain conditions. *Brit. J. Anaesth.* 52: 247 - 252, 1980.
- Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E. and Gilbert, P.E. The effects of morphine and nalorphine-like drugs in the nondependent and morphine dependent spinal dog. *J. Pharmacol. Exp. Ther.* 197: 517 - 532, 1976.



- Morely, J.S. Nomenclature. *Neuropeptides* 1: 231 - 235, 1981.
- Mudge, A.W., Leeman, S. and Fishback, G.D. Enkephalin inhibits release of substance P from sensory neurons in culture and decreases action potential duration. *Proc. Nat. Acad. Sci. USA* 76: 526 - 530, 1979.
- Munson, P.J. and Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand binding systems. *Analyt. Biochem.* 107: 220 - 229, 1980.
- Noda, M., Furutani, Y., Takahashi, H., Toyosato, M., Hirose, T., Inayama, S., Nakanishi, S. and Numa, S. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. *Nature* 295: 202 - 206, 1982.
- Nakanishi, S., Inoue, A., Kita, T., Nakamura, M., Chang, A.C.Y., Cohen, S.N. and Numa, S. Nucleotide sequence of cloned cDNA for bovine corticotropin- $\beta$ -lipotropin precursor. *Nature* 278: 423 - 427, 1979.
- Pasternak, G.W., Childers, S.R. and Snyder, S.H. Opioid analgesia: Evidence for mediation by a subpopulation of opiate receptors. *Science* 208: 514 - 516, 1980.
- Pasternak, G.W., Snowman, A.M. and Snyder, S.H. Selective enhancement of [ $^3\text{H}$ ] opiate agonist binding by divalent cations. *Mol. Pharmacol.* 11: 735 - 744, 1975.
- Paton, W.D.M. The action of morphine and related substances on contraction and acetylcholine output of coaxially stimulated guinea-pig ileum. *Brit. J. Pharmacol. Chemother.* 12: 119 - 127, 1957.
- Pert, C.B., Snyder, S.H. Opiate receptor: demonstration in nervous tissue. *Science* 179: 1011 - 1014, 1973a.
- Pert, C.B., Snyder, S.H. Properties of opiate-receptor binding in rat brain. *Proc. Nat. Acad. Sci. USA* 70: 2243 - 2247, 1973b.
- Pert, C.B., Snyder, S.H. Opiate receptor binding of agonists and antagonists affected differently by sodium. *Molecular Pharmacology* 10: 868 - 879, 1974a.
- Pert, C.B., Snowman, A.M., and Snyder, S.H. Localization of opiate receptor binding in synaptic membranes of rat brain. *Brain Research* 70: 184 - 188, 1974b.

- Pert, C.B., Snyder, S.H. Identification of opiate receptor binding in intact animals. *Life Sci.* 16: 1623 - 1634, 1975.
- Pert, C.B., Kuhor, M.J. and Snyder, S.H. Opiate receptor autoradiographic localization in rat brain. *Proc. Nat. Acad. Sci. USA* 73: 3729 - 3733, 1976.
- Peterson, G.L. A simplification of the protein assay method of Lowery et. al. which is more generally applicable. *Analytical Biochemistry* 83: 346 - 356, 1977.
- Pfeiffer, A. Pasi, A., Mehraein, P. and Herz, A. A subclassification of k-sites in human brain by use of dynorphin 1-17. *Neuropeptides* 2: 89 - 97, 1981.
- Quirion, R., Hammer, R.P., Jr., Herkenham, M and Pert, C.B. The phencyclidine (angle dust)/sigma "opiate" receptor: visualization by tritium-sensitive film. *Proc. Nat. Acad. Sci. USA* 78: 5881 - 5885, 1981.
- Romagnoli, A., and Keats, A.S. Ceiling effect for respiratory depression by nalbuphine. *Clin. Pharmacol. Ther.* 27: 478 - 485, 1980.
- Ruda, M.A. and Gobel, S. Ultrastructural characterization of axonal endings in the substantia gelatinosa which take up [ $^3$ H]serotonin. *Brain Res.* 184: 57 - 83, 1980.
- Ruda, M.A. Opiates and pain pathways: demonstration of enkephalin synapses on dorsal horn projection neurons. *Science* 215: 1523 - 1525, 1982.
- Ruda, M.A., Allen, B., and Gobel, S. Ultrastructural characterization of noradrenergic axonal endings in layers I and II of the dorsal horn of the medulla. *Soc. Neurosci. abstr.* 5: 712
- Ruda, M.A. Coffield, J. and Dubner, R. Demonstration of postsynaptic opioid modulation of thalamic projection neurons by the combined techniques of retrograde horseradish peroxidase and enkephalin immunohistochemistry. *J. Neuroscience* 4: 2117 - 2132, 1984.
- Schamauss, C., Doherty, C. and Yaksh, T.L. The analgetic effects of an intrathecally administered partial opiate agonist, Nalbuphine Hydrochloride. *Euro. J. Pharmacol.* 86: 1 - 7, 1983.
- Schubert, D.P., Wuster, M. Stoiber, R. and Herz, A. A selective distribution of different

- opiate receptors in certain area of rat brain as revealed by in vitro autoradiography. *Neurosci. Cell.* 21:119 - 124, 1981.
- Scott, D.B. and McClure, J. Selective epidural analgesia. *Lancet* 1410 - 1411, 1979.
- Sharma, S.K., Nirenberg, M. and Klee, W.A. Morphine receptors as regulators of adenylate cyclase activity. *Proc. Natl. Acad. Sci. USA* 72: 590 - 594, 1975.
- Sugimoto, T. and Gobel, S. Primary neurons maintain their central axonal arbors in spinal dorsal horn following peripheral nerve injury: an anatomical analysis using transganglionic transport of horseradish peroxidase. *Brain Res.* 248: 377 - 381, 1982.
- Sumal, K.K., Pickel, U.M., Miller, R.J. and Reis, D.J. Enkephalin-containing neurons in substantia gelatinosa of spinal trigeminal complex: Ultrastructure and synapse interaction
- Simon, E.J., Hiller, J.M. and Edelman, I. Stereospecific binding of the potent narcotic analgesic [<sup>3</sup>H] etorphine to rat brain homogenate. *Proc. Nat. Acad. Sci. USA* 70: 1947 - 1949, 1973.
- Teschmacher, H., Opheim, K.E., Cox, B.M. and Goldstein, A. A peptide-like substance from pituitary that acts like morphine. 1. Isolation. *Life Sci.* 16: 1771 - 1776, 1975
- Terenius, L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. *Acta Pharmacology Toxicology* 32: 317 - 320, 1973.
- Terenius, L. and Wahlstrom, A. Morphine-like ligand for opiate receptors in mammalian brain. *Acta Pharmacol. Toxicol.* 35: 55 - 59, 1974
- Wang, J.K., Analgesic effect of intrathecally administered morphine. *Regional Anesthesia* 2 : 3 - 8, 1977.
- Wang, J. K., Nauss, L.A. and Thomas, J.E. Pain relief by intrathecally applied morphine in man. *Anesthesiology* 50 : 149 - 151, 1979.
- Werling, L.L., Zarr, G. and Cox, B.M. Characteristics of opioid agonist binding sites in guinea pig and rat neural tissues at 37°. *Abstr of IUPHAR 9th International Congress of*



- Pharmacology, London, 1984a.
- Werling, L.L., Brown, S.R., and Cox, B.M. The sensitivity of opioid receptor types to regulation by sodium and GTP. *Neuropeptides* (in press), 1984b.
- Werling, L.L., Zarr, G., Brown, S. and Cox, B.M. Opioid binding characteristics of rat and guinea pig brain membranes in the presence of physiological cations at 37°. (Submitted) 1984c.
- Werz, M.A. and MacDonald, K.L. Dynorphin reduces calcium-dependent action potential duration by decreasing voltage-dependent calcium conductance. *Neurosci. Ltrs.* 46: 185 - 190, 1984.
- Wood, P.L. Multiple opiate receptors: support for unique mu, delta and kappa sites. *Neuropharmacology* 21: 487 - 497, 1982.
- Yaksh, T.L. and Rudy, T.A. Chronic catheterization of the spinal subarachnoid space. *Physiol. Behav.* 17: 1031 - 1036, 1976a.
- Yaksh, T.L. and Rudy, T.A. Analgesia mediated by a direct spinal action of narcotics. *Science* 192: 1357 - 1358, 1976b.
- Yaksh, T.L. Analgesic actions of intrathecal opiates in cat and primate. *Brain Res.* 153: 205 - 210, 1978.
- Yaksh, T.L. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal gray. *Brain Res.* 160: 180 - 185, 1979.
- Yaksh, T.L., Jessell, T.M., Gamse, R., Mudge, A.W. and Leeman, S.E. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. *Nature* 286: 155 - 157, 1980.
- Yaksh, T.L. Spinal opiate analgesia: characteristics and principles of action. *Pain* 11: 293 - 346, 1981.
- Yaksh, T.L. Multiple spinal opiate receptor systems in analgesia. *Advances in Pain Research and Therapy* 6: 197 - 215, 1984.



Yoshimura, M. and North, R.A. Substantia gelatinosa neurons in vitro hyperpolarized by enkephalin. *Nature* 305: 529 - 530, 1984.

Zukin, R.S., Zukin, S.R. The case for multiple opiate receptors. *TINS* 1 - 4, 1984.